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ABSTRACT 
Vascular endothelial growth factors (VEGFs) are considered as potential therapeutic agents 
to induce blood vessel formation in ischemic tissues when normal blood flow is 
compromised. VEGFs exist as antiparallel dimers and they share a highly conserved VEGF 
homology domain (VHD), which is responsible for binding to VEGF receptor 2 (VEGFR-2), 
the major angiogenic signaling receptor. Binding of VEGF to its receptor activates several 
downstream signaling cascades leading to endothelial cell (EC) proliferation, migration, 
survival, and increased vascular permeability. The aim of this thesis was to find out, how 
the small structural differences and receptor binding properties of different VEGFs affect 
the biological outcomes, and if VEGFs can be modified to prevent VEGF-induced, 
unwanted side-effects and to improve pro-angiogenic therapies.  
In the first study, the relevance of the cysteine residues at VEGF-DΔNΔC dimer interface 
was studied. VEGF-DΔNΔC is predominantly a non-covalent dimer, but the conserved 
cysteines (Cys-44 and Cys-53), forming the intersubunit covalent disulfide bridge in other 
VEGFs, were found to be essential also for the function of VEGF-DΔNΔC. VEGF-DΔNΔC has 
also an unpaired cysteine (Cys-25), and its substitution with various amino acids improved 
the biological activity of VEGF-DΔNΔC. This was mainly due to a more stable protein 
structure, since after the elimination of the free thiol group, a disulfide bond was more 
likely to form between intermolecular Cys-44 and Cys-53. In the second study, the 
angiogenic properties of several VEGFR-2 ligands were compared. VEGFR-2 activation was 
found to depend on the binding affinity of the VEGF ligand, but the phosphorylation 
pattern and major downstream signaling pathways were similar between tested VEGFs. 
VEGFR-2 activation alone was sufficient to induce EC proliferation, tube formation, and 
vascular permeability, but VEGF binding to Neuropilin (Nrp) strengthened the angiogenic 
potency of VEGF without having an additive effect on vascular permeability. These results 
emphasize moderate VEGFR-2, but high Nrp binding affinities as favorable features of 
VEGF. In the third study, the role of Slit2, a regulator of vascular remodeling, was studied 
for the first time in a large animal model. We found that Slit2 restrained Vammin- and 
VEGF-DΔNΔC-induced increase in blood perfusion, capillary size, and vascular permeability 
in rabbit skeletal muscles. This was at least partly due to the reduced eNOS activation 
levels. Slit2 was also shown to downregulate several angiogenesis-related genes. 
In conclusion, the results from the thesis can be used for the design of novel VEGFR-2 
ligands with improved therapeutic properties and to develop new strategies for the 
treatment of ischemic diseases. 
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TIIVISTELMÄ 
Ihmisen verisuonen endoteelikasvutekijät (VEGF) ovat mahdollisia hoidollisia yhdisteitä 
saamaan aikaan verisuonten uudismuodostusta hapenpuutteesta kärsivissä kudoksissa, 
joihin normaali verenvirtaus on estynyt. VEGF-proteiinit esiintyvät antiparalleellisina 
dimeereinä, ja eri perheenjäseniä yhdistää samankaltainen VEGF-homologiadomeeni 
(VHD), minkä välityksellä proteiinit sitoutuvat VEGF reseptori 2:een (VEGFR-2). 
Sitoutuminen reseptoriin käynnistää useita signaalireittejä johtaen endoteelisolujen 
lisääntymiseen, liikkumiseen kudoksessa, selviytymiseen ja verisuonten läpäisevyyden 
kasvuun. Väitöskirjatyön tavoitteena oli selvittää, kuinka eri VEGF-proteiinien pienet 
rakenne-erot ja reseptoreihin sitoutumisominaisuudet vaikuttavat niiden biologisiin 
vasteisiin ja onko muokkauksia tekemällä mahdollista estää VEGF-proteiinien käytöstä 
johtuvia sivuvaikutuksia tehokkaamman uudisverisuonituksen mahdollistamiseksi.  
Ensimmäisessä osatyössä tutkittiin VEGF-DΔNΔC:n dimeeripinnan 
kysteiiniaminohappojen merkitystä. VEGF-DΔNΔC esiintyy pääasiassa ei-kovalenttisena 
dimeerinä, mutta kysteiinien 44 ja 53, jotka muilla VEGF-kasvutekijöillä muodostavat 
kovalenttisen disulfidisidoksen kahden monomeerin välille, havaittiin olevan 
välttämättömiä myös VEGF-DΔNΔC:n toiminnan kannalta. VEGF-DΔNΔC:n rakenteessa on 
lisäksi ylimääräinen kysteiini 25, ja tämän kysteiinin korvaaminen useilla muilla 
aminohapoilla lisäsi VEGF-DΔNΔC:n biologista aktiivisuutta. Tämä johtui pääasiassa 
vakaammasta proteiinirakenteesta, sillä vapaan tioliryhmän poistamisen jälkeen kysteiinien 
44 ja 53 välille pystyi todennäköisemmin muodostumaan disulfidisidos. Toisessa osatyössä 
vertailtiin usean VEGFR-2:n ligandin verisuonten uudismuodostukseen vaikuttavia 
ominaisuuksia. VEGFR-2:n aktivaatiotehon todettiin riippuvan VEGF-ligandin 
sitoutumisvoimakkuudesta reseptoriin, mutta VEGFR-2:n aktivaatiotapa ja tärkeimpien 
signaalireittien aktivoituminen olivat samanlaisia VEGF-proteiinien kesken. Yksin VEGFR- 
2:n aktivoituminen oli riittävää saamaan aikaan endoteelisolujen lisääntymistä, 
putkimaisten rakenteiden muodostumista ja verisuonten läpäisevyyden kasvua, mutta 
VEGF-proteiinien sitoutuminen Neuropilineihin (Nrp) vahvisti verisuonten 
uudismuodostustehoa lisäämättä enempää suonten läpäisevyyttä. Nämä tulokset 
tähdentävät VEGF-ligandien suotuisiksi ominaisuuksiksi kohtalaista VEGFR-2 mutta 
voimakasta Nrp sitoutumisvoimakkuutta. Kolmannessa osatyössä tutkittiin verisuonten 
muokkaukseen osallistuvan Slit2:n roolia ensimmäistä kertaa isossa koe-eläinmallissa. 
Slit2:n osoitettiin hillitsevän Vamminin ja VEGF-DΔNΔC:n aiheuttamaa veren virtauksen, 
kapillaarikoon ja kapillaarien läpäisevyyden kasvua kanin alaraajan lihaksessa. Tämä johtui 
ainakin osittain eNOS-signaalireitin aktivoitumisen estämisestä. Slit2:n osoitettiin myös 
säätelevän negatiivisesti useita uudisverisuonitukseen liittyviä geenejä. 
Yhteenvetona voidaan todeta, että väitöskirjan tuloksia voidaan hyödyntää 
suunniteltaessa uusia kehittyneempiä ominaisuuksia omaavia VEGFR-2:n ligandeja 
hoitokäyttöön ja kehittäessä uusia hoitomuotoja hapenpuutteesta johtuviin sairauksiin. 
Luokitus: QU 107, QU 375, WG 500 
Yleinen Suomalainen asiasanasto: angiogeneesi; VEGF-reseptori-2; ligandit; signaalitransduktio 
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 1 Introduction  
Cardiovascular diseases are the leading cause of death worldwide. Gene therapy with pro-
angiogenic growth factors offers a new way to promote blood vessel formation in ischemic 
conditions, such as coronary (CAD) and peripheral artery diseases (PAD). The benefits of 
gene therapy over conventional strategies include the local and targeted treatment of the 
affected tissue and a possibility for long-lasting effects (Yla-Herttuala, Alitalo 2003). 
Vascular endothelial growth factors (VEGFs) belong to the key candidates for inducing new 
therapeutic vascular formation. The VEGFs bind with different specificities to VEGF 
receptors 1-3 (VEGFR-1-3) located at the endothelial cell (EC) surface. Some VEGF forms 
also bind to different coreceptors, such as Neuropilins (Nrp) and the components of the 
extracellular matrix (ECM), after alternative splicing or proteolytic modifications. The main 
mediator of VEGF-induced angiogenic effects is VEGFR-2. The activation of the VEGFR-2 
receptor leads to EC proliferation, migration, survival, and increased vascular permeability, 
all of which are required for angiogenesis to take place. The increased vascular 
permeability might lead to transient edema formation in tissues, and this VEGF-induced 
side-effect should be minimized in order to improve the outcome of pro-angiogenic 
therapies (Yla-Herttuala et al. 2007).  
VEGFs and their receptors are not the only players involved in the complex angiogenic 
process, which requires signals to initiate and sustain the vessel growth and signals for 
vessel remodeling and stabilization. The Slit protein family of neuronal guidance molecules 
and their Roundobout (Robo) receptors are also recognized as regulators of angiogenesis, 
but their precise role in the vasculature has remained unclear. Slit-Robo signaling leads to 
changes in cell cytoskeleton, thus influencing cell migration, but the results in ECs have 
been either pro- or anti-angiogenic (Yuen, Robinson 2013). 
When designing improved pro-angiogenic therapies based on the use of VEGFs, the 
knowledge of the biology of these growth factors is essential. In this thesis, the structures 
and properties of different VEGFR-2 ligands were studied to find out the key molecular 
determinants affecting to their angiogenic effects. Also, some ways in which VEGFR-2 
ligands could be modified to reduce the side-effects without losing the high angiogenic 
potency are described. The thesis also describes studies of the role of Slit2 in angiogenesis 
and its beneficial use in combination with VEGFs to reduce vascular leakage in therapeutic 
angiogenesis. 
 
 
 
2 
3 
2  Review of the literature
2.1 VASCULAR SYSTEM 
2.1.1 Overview of the vascular system 
Vascular system is composed of blood circulation and lymphatic system. Oxygen, nutrients, 
hormones, and cellular waste products are transported through blood vessels to and away 
from tissues, and lymph vessels carry lymphatic fluid extravasated from the blood vessels. 
There are three major types of blood vessels: arteries, capillaries, and veins. Arteries are 
elastic and muscular, and they transport oxygenated blood away from the heart. The artery 
wall consists of three morphologically different layers: intima, media, and adventitia. 
Intima is the innermost layer, and it is lined by ECs. Media is composed of a thick layer of 
smooth muscle cells (SMCs), and adventitia is made of connective tissue (Hall 2010). 
Arteries are branched into smaller arterioles that carry blood to capillaries. Arterioles have 
a thinner SMC layer. Capillaries are responsible for exchanging gases, nutrients, and waste 
products between blood plasma and interstitium. Capillaries have thin walls favouring gas 
diffusion, and pericytes give them structural support. Venules pick up blood from 
capillaries, and blood is transported to larger veins that return blood back to the heart. 
Thin-walled veins have relatively big lumens, and they are less muscular than arteries. To 
prevent blood backflow, some veins contain valves. Like blood vessels, lymphatic vessels 
have an inner endothelial cell layer, and collecting lymphatic vessels also contain SMCs and 
valves (Hall 2010). 
2.1.2 Vasculogenesis, angiogenesis, and arteriogenesis 
During embryogenesis, two different mechanisms, vasculogenesis and angiogenensis, are 
responsible for the formation of vascular network. Vasculogenesis begins when 
hematopoietic cells and angioblasts differentiate from hemangioblasts of the mesoderm. 
Endothelial cells of arteries and veins form from differentiating angioblasts and organize 
into primitive vascular plexus. Fibroblast growth factor 2 (FGF-2), VEGF-A, VEGFR-1-3, 
and Nrp coreceptors belong to the key factors critical for normal vasculogenesis (Risau 
1997, Carmeliet 2000, Patel-Hett, D'Amore 2011).  
After the primary vascular network has formed in the developing embryo, new 
capillaries start to form either by sprouting or splitting from the pre-existing capillaries 
(Patan 2000). In sprouting angiogenesis, endothelial cells start to release proteases 
degrading the basement membrane. This enables endothelial cells to migrate towards 
angiogenic stimuli to the surrounding matrix, proliferate, and form sprouts between 
neighbouring vessels. The sprouts organize into vessel lumen. In splitting or 
intussusceptive angiogenesis, the capillary wall extends into the lumen to split a vessel in 
two. First, opposing capillary walls protrude into the lumen and create a contact zone 
between endothelial cells. After the endothelial bilayer is perforated, a transluminal pillar 
with an interstitial core is formed which is then invaded by myofibroblasts and pericytes, 
leading to its rapid enlargement. During the final phase, the pillars increase in girth 
without undergoing any further change in their basic structure. Intussuspective 
angiogenesis enables rapid vascular growth and there is no need of proliferation of the 
endothelial cells, which saves resources needed elsewhere in the developing embryo (Patan 
2000, Djonov, Baum & Burri 2003).   
Remodeling of the vascular network is necessary for its proper function. In addition to 
new vessel formation, old vessels are deleted. The newly formed vessels remain fragile 
until they are surrounded by perivascular structures. During the maturation process, mural 
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cells, such as pericytes and SMCs, cover nascent vessels providing structural support and 
protecting against rupture or regression. Mural cells also inhibit endothelial cell 
proliferation and migration thereby stabilizing newly-formed vessels (Carmeliet 2000, 
Patan 2000).  
Several factors have been shown to be involved in the proper regulation of angiogenesis, 
vessel remodeling, and stabilization, such as VEGFs, VEGFR-1-3, angiopoietin 1 and 2 
(Ang1/2) and their Tie receptors, Platelet-derived growth factor (PDGF), Transforming 
growth factor-β (TGF-β), several neuronal guidance molecules, as well as Delta-like ligand 
4 (Dll4) and its Notch receptor (Risau 1997, Patel-Hett, D'Amore 2011). Hypoxia triggers 
angiogenesis in response to the metabolic needs of tissues. Hypoxia inducible factor (HIF) 
binds to the hypoxia response element (HRE) in the promoter area of several target genes, 
such as VEGF-A, activating their transcription. Hypoxia also stabilizes VEGF-A messenger 
RNA (mRNA) (Risau 1997).  
In adults, angiogenesis is the main way to form new blood vessels in both physiological 
and pathological conditions (Byrne, Bouchier-Hayes & Harmey 2005). In a healthy adult, 
angiogenesis is mainly restricted to processes such as wound healing and the menstrual 
cycle. Pathological conditions include several complex diseases, like cancer, atherosclerosis, 
age-related macular degeneration, diabetic retinopathy, psoriasis, and arthritis (Byrne, 
Bouchier-Hayes & Harmey 2005).  
Arteriogenesis is defined as the growth and maturation of collateral arterioles into larger 
conductance arteries (Schaper, Scholz 2003). It is the most important mechanism for rapid 
vessel growth to restore blood flow in ischemic areas. Arteriogenesis takes place when the 
main functional artery is occluded, a blood pressure gradient is formed, and blood flow 
increases in collateral circulation. This activates the endothelium of the collateral vessel, 
and nitric oxide (NO) is produced inducing collateral dilatation. Also, circulating 
monocytes are recruited to produce growth factors and proteases leading to endothelial 
proliferation. In contrast to angiogenesis, where the driving force is oxygen unavailability 
and subsequent ischemia, arteriogenesis takes place under normal oxygen levels and is 
triggered by shear stress along the vessel wall (Schaper, Scholz 2003). 
2.1.3 Lymphangiogenesis 
Lymphangiogenesis begins in the embryo after the formation of the blood vasculature. It 
takes place when venous endothelial cells differentiate into lymphatic endothelial cells. The 
lymphatic system is a blind ended, one-way system, which transports protein-rich liquid 
and lymphocytes extravasated from the blood vessels back into the circulation (Jussila, 
Alitalo 2002). Lymph is transported from lymphatic capillaries into collecting lymphatic 
vessels and finally through the thoracic duct into the venous circulation. On the way, 
lymph is filtered in the lymph nodes. Interstitial fluid is passed through the lymphatic 
vessel wall quite freely. This is not the situation in blood vessels where vessel wall 
permeability is tightly regulated. Lymph fluid does not contain red blood cells or platelets, 
which makes it less coagulable than blood. Lymphatic vessels have an important role in the 
immune system, since they transport antigens and antigen-presenting cells to the lymph 
nodes where lymphocytes reside. The key regulators of lymphatic vessel growth in the 
developmental stage include Prox-1, VEGF-C, and VEGFR-3 (Alitalo, Tammela & Petrova 
2005). 
2.2 BIOLOGY OF THE VASCULAR ENDOTHELIAL GROWTH FACTORS 
The VEGF family of secreted glycoproteins contains five members found in humans, VEGF-
A, -B, -C, -D, and Placental growth factor (PlGF), as well as VEGF-E and VEGF-F encoded 
by Orf viruses and found in snake venoms, respectively. The VEGFs influence the 
development and growth of blood and lymphatic vessels during embryogenesis, they 
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maintain vascular homeostasis and participate in physiological and pathological conditions 
in adults, and VEGFs are also recognized as key molecules for inducing therapeutic 
angiogenesis in ischemic myocardium and peripheral skeletal muscles (Yla-Herttuala et al. 
2007). VEGFs selectively bind to the cell surface receptor tyrosine kinases (RTKs) VEGFR-1 
(Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 (Flt-4). In addition, different VEGF isoforms 
bind to the coreceptors Nrp-1 and Nrp-2 and on the cell surface heparan sulfate 
proteoglycans (HSPGs) and integrins. The binding of VEGFs to their receptors is 
summarized in Figure 1. The three-dimensional structures or the structures of the receptor 
binding domains have been resolved for all the family members. All VEGFs share a 
common VEGF homology domain (VHD) in their tertiary structure containing the binding 
sites for different VEGF receptors. In the VHD region, all VEGFs have a conserved cysteine 
knot motif, characterized by eight cysteine residues, leading to antiparallel VEGF 
dimerization (Grunewald et al. 2010).  
 
 
Figure 1. The receptor binding profiles of different VEGFs. VEGFs bind with different specificities 
to cell surface RTKs. In addition to binding to VEGFR-1, -2, and -3, some VEGF isoforms also 
bind to the coreceptors Nrp-1, Nrp-2, HSPGs, and integrins. The proteolytical processing of 
VEGF-C and VEGF-D increases their affinity towards VEGFR-2 and -3. 
2.2.1 VEGF-A 
VEGF-A was originally isolated from tumors as the agent causing vascular permeability 
and named as vascular permeability factor (VPF) (Senger et al. 1983). Later, VEGF-A was 
found to be the key regulator of vasculogenesis and angiogenesis (Ferrara, Henzel 1989, 
Leung et al. 1989). The loss of a single Vegfa allele leads to abnormal vessel development 
and embryonic lethality (Carmeliet et al. 1996). In human tissues, VEGF-A expression is the 
highest in adult lung, kidney, heart, and adrenal gland. VEGF-A contains eight exons, and 
alternative splicing of its mRNA gives rise to at least six isoforms, containing 121, 145, 165, 
183, 189, and 206 amino acids, respectively. The isoforms differ from their C-terminal ends 
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leading to differences in binding to the coreceptors Nrp-1 and Nrp-2 as well as HSPGs, 
which sequester VEGF-A to ECM (Delcombel et al. 2013). Exons 1-4 (E1-E4), found in all of 
the isoforms, encode the signal sequence as well as sequences responsible for the VEGFR-1 
and -2 binding. Nrp binding is mediated by the C-terminal E8a-encoded domain in 
cooperation with E5 and/or E7 encoded domains (Soker et al. 1996, Parker et al. 2012, 
Delcombel et al. 2013). Previously, it was thought that only the E7 containing isoforms, like 
VEGF-A165, VEGF-A183, VEGF-A189, and VEGF-A206, are able to bind to Nrp-1, but later, E8a 
was emphasized as the major Nrp-1 binding site, since also VEGF-A121, which lacks the E7, 
was found to bind to Nrp-1 (Soker et al. 1998, Pan et al. 2007b). VEGF-A145 and VEGF-A165 
have been reported to bind to Nrp-2 (Gluzman-Poltorak et al. 2000). HSPG binding sites 
have been mapped to the E6- and E7-encoded domains (Houck et al. 1991, Houck et al. 
1992) but also E8a might contribute (Delcombel et al. 2013). Among the most abundant 
isoforms, VEGF-A121 is freely soluble, but instead, VEGF-A189 is tightly bound to the cell 
surface. VEGF-A165 lacks the other HSPG binding domain and is thus partly soluble and 
partly bound to the ECM. VEGF-A isoforms having the sequence encoded by the E8a are 
reported to be pro-angiogenic while those having the sequence encoded by the E8b are 
reported to be much less active, and they might poses both anti-angiogenic (Bates et al. 
2002, Rennel et al. 2008, Woolard et al. 2004, Rennel et al. 2009) and pro-angiogenic features 
(Catena et al. 2010). The angiogenic potency of VEGF-A has been proven in several in vitro 
and in vivo studies (Rissanen et al. 2003, Korpisalo et al. 2011, Delcombel et al. 2013), and 
also in many clinical studies involving human patients (Yla-Herttuala et al. 2007, Giacca, 
Zacchigna 2012). 
2.2.2 PlGF 
PlGF was identified in placenta, and it was shown to resemble VEGF-A (Maglione et al. 
1991). In addition to placenta, PlGF expression is detected for example in heart and lungs. 
Splicing of its mRNA generates four isoforms, PlGF-1-4, from which PlGF-2 and PlGF-4 are 
capable of binding to HSPGs (Maglione et al. 1993, Cao et al. 1997, Yang et al. 2003). PlGF-2 
has also been shown to bind to Nrp-1 and Nrp-2 (Migdal et al. 1998, Gluzman-Poltorak et 
al. 2000, Mamluk et al. 2002). It is likely that also PlGF-4 is able to bind to Nrps via its 
heparin binding domain (Yang et al. 2003). PlGF binds to VEGFR-1 as a homodimer, but it 
is also capable of forming heterodimers with VEGF-A and in that way bind to VEGFR-2 
(Park et al. 1994, Cao et al. 1996). PlGF binds to VEGFR-1 with a higher affinity than its 
other ligands VEGF-A and VEGF-B, and PlGF binding to VEGFR-1 has been shown to 
phosphorylate a unique set of VEGFR-1 tyrosine residues (Olofsson et al. 1998, Autiero et 
al. 2003). In addition, PlGF binding to VEGFR-1 might transphosphorylate VEGFR-2 
(Autiero et al. 2003). PlGF has been shown to induce endothelial cell proliferation, 
migration, and survival, and it has been shown to be angiogenic or arteriogenic in many 
animal models (Dewerchin, Carmeliet 2012, Anisimov et al. 2013a). The deletion of the Plgf 
gene does not affect the vascular development in mice, but in adults, its absence impairs 
angiogenesis, plasma extravasation, and collateral formation during ischemia, 
inflammation, wound healing, and cancer (Carmeliet et al. 2001).  Recently, PlGF was 
shown to bind and activate VEGFR-1 differentially compared to VEGF-B explaining their 
distinct biological outcomes (Anisimov et al. 2013a). The angiogenic effects mediated by 
PlGF may also result from PlGF displacing VEGF-A from VEGFR-1, which makes more 
VEGF-A available to bind to VEGFR-2, the main receptor mediating angiogenesis 
(Carmeliet et al. 2001, Roy et al. 2005). 
2.2.3 VEGF-B 
VEGF-B resembles structurally VEGF-A and PlGF. It is expressed most abundantly in 
tissues with high metabolic activity, like myocardium, skeletal muscle, and adipose tissue 
(Olofsson et al. 1996a, Bry et al. 2014). The alternative splicing of its mRNA generates two 
isoforms, VEGF-B167 and VEGF-B186 (Olofsson et al. 1996b). Both of the isoforms bind to 
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VEGFR‐1 and Nrp‐1. However, the binding of VEGF‐B167 to Nrp‐1 is dependent on heparin, 
and  VEGF‐B186  binding  to  Nrp‐1  requires  proteolytic  processing  (Olofsson  et  al.  1998, 
Makinen et al. 1999). The  two  isoforms differ by  their biochemical properties: VEGF‐B167, 
with a heparin‐binding domain in its C‐terminus, binds to HSPGs and is sequestered to the 
ECM, but VEGF‐B186, at least when uncleaved, is freely soluble (Olofsson et al. 1996a). The 
precise role of VEGF‐B has remained unclear despite extensive research. VEGF‐B is not able 
to  induce  efficient VEGFR‐1 dimerization and  signaling, and  it  seems  that  in  endothelial 
cells,  the  role of VEGF‐B  is  to block VEGF‐A  from binding  to VEGFR‐1 making VEGF‐A 
more available to VEGFR‐2 (Anisimov et al. 2013a, Kivela et al. 2014). Adenoviral VEGF‐B 
gene  transfer  has  been  shown  to  induce  myocardium‐specific  angiogenesis  and 
arteriogenesis, but in skeletal muscle or periadventitial tissue, VEGF‐B has not been able to 
induce  vessel  growth  implying  that  VEGF‐B‐induced  angiogenic  effects  seem  to  be 
restricted to the heart (Bhardwaj et al. 2003, Rissanen et al. 2003, Li et al. 2008, Lahteenvuo 
et al. 2009). Mice lacking Vegfb gene are healthy and fertile and do not show any changes in 
cardiac  structural  or  functional  parameters  (Dijkstra  et  al.  2014).  VEGF‐B  has  been 
suggested to have a role in controlling endothelial fatty acid uptake and transport in heart 
and skeletal muscle (Karpanen et al. 2008, Hagberg et al. 2010). However, these results have 
been  challenged  with  new  reports  showing  that  VEGF‐B  is  dispensable  for  cardiac 
metabolism and fatty acid uptake (Dijkstra et al. 2014, Kivela et al. 2014). 
2.2.4 VEGF‐C and VEGF‐D 
VEGF‐C  and  VEGF‐D  closely  resemble  each  other:  their  effects  are  mediated  through 
VEGFR‐2 and ‐3, and they are both produced as precursor proteins which consist of long N‐ 
and C‐terminal propeptides flanking VHD that contains the receptor binding sites (Joukov 
et al. 1996, Achen et al. 1998). VEGF‐C and  ‐D are proteolytically processed from their N‐ 
and C‐terminal ends  to  form  the major VHD homodimers, VEGF‐CΔNΔC and VEGF‐DΔNΔC, 
which bind with much higher affinities to their receptors than the full‐length forms (Joukov 
et  al.  1997,  Stacker  et  al.  1999a).  The  first  proteolytic  cleavage  by  furins  releases  the C‐
terminal end from the VHD, and after the second cleavage by extracellular serine proteases 
including plasmin, the major forms are produced (Figure 2) (Stacker et al. 1999a, McColl et 
al.  2003,  Siegfried  et  al.  2003). The unprocessed  full‐length dimers  are  covalently  bound 
through disulfide bonds, but instead, the processed forms are mainly non‐covalently bound 
dimers  although  they  have  the  conserved  cysteine  residues  that  form  the  interchain 
disulfide bonds  in other VEGFs  (Joukov et al. 1997, Stacker et al. 1999a). VEGF‐CΔNΔC and 
VEGF‐DΔNΔC have been shown to induce angiogenesis through VEGFR‐2 both in vitro and in 
vivo  (Joukov et al. 1997, Marconcini et al. 1999, Hiltunen et al. 2000, Rissanen et al. 2003, 
Rutanen  et  al.  2004).  When  binding  to  VEGFR‐3,  VEGF‐C  and  ‐D  induce 
lymphangiogenesis in tissues and tumors (Makinen et al. 2001, Stacker et al. 2001, Veikkola 
et al. 2001, Lahteenvuo et al. 2011). During development, VEGF‐C is expressed along with 
VEGFR‐3 in the areas where lymphatic vessels are developed (Kukk et al. 1996, Karkkainen 
et al. 2004). Mice lacking Vegfc gene do not develop lymphatic vessels leading to embryonic 
lethality,  and mice  heterozygous  for Vegfc  have  impaired  lymphatic  vessel development 
and  lymphedema  (Karkkainen  et  al.  2004).  In  contrast,  Vegfd  gene  is  dispensable  for 
lymphatic vessel development  (Baldwin et al. 2005).  In adults, VEGF‐C  is expressed most 
prominently  in heart, placenta, ovary,  small  intestine,  and  the  thyroid gland. VEGF‐D  is 
found  particularly  in  lung,  heart,  skeletal  muscle,  colon,  and  small  intestine.  The 
propeptides of VEGF‐C and ‐D mediate binding to Nrp‐1 and Nrp‐2 (Karpanen et al. 2006). 
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Figure 2. VEGF-C and VEGF-D processing. 1. VEGF-C and -D are produced as preproproteins 
composed of an N-terminal signal sequence, N-terminal propeptide, VHD, and C-terminal 
propeptide. 2. Unprocessed forms are secreted from cells as covalently bound dimers where 
disulfide bonds are formed between opposite N- and C-terminal ends. 3. The first proteolytical 
cleavage releases the C-terminal end, which is still bound to the opposing N-terminal propeptide 
through disulfide bonds. 4. The second cleavage releases both the N-terminal propeptide and 
the opposing C-terminal propeptide. 5. Fully processed forms, VEGF-CΔNΔC and VEGF-DΔNΔC, 
consist of a VHD dimer existing predominantly as non-covalently bound form. 
2.2.5 VEGF-E and VEGF-F 
The viral VEGF homolog, VEGF-E, was discovered in the genome of Orf-virus (Lyttle et al. 
1994). The different strains of the virus encode for variable VEGF-E forms that all bind to 
VEGFR-2 and induce angiogenic effects both in vitro and in vivo (Ogawa et al. 1998, Meyer 
et al. 1999, Wise et al. 1999, Kiba et al. 2003). Some forms also bind to Nrp-1 and Nrp-2 
(Wise et al. 2003, Cebe-Suarez et al. 2008). Humanized chimeric molecules composed of 
VEGF-ENZ7 and PlGF-1 have been developed for reduced antigenicity in therapeutic use 
(Zheng et al. 2006). These chimeras were shown to activate VEGFR-2 and induce less 
vascular permeability compared to VEGF-A and no inflammatory response (Zheng et al. 
2006). 
Several VEGF-F proteins have been isolated from different snake venoms (Komori et al. 
1999, Yamazaki et al. 2003, Nakamura et al. 2014). Vammin and VR-1 have been shown to 
bind to VEGFR-2 with high affinity, they contain short C-terminal heparin binding tails, 
and they have been shown to induce vascular permeability and hypotension (Yamazaki et 
al. 2003, Yamazaki et al. 2005, Yamazaki et al. 2007). Recently, a new VEGF-F form, which 
binds to VEGFR-2, but not heparin, was identified (Nakamura et al. 2014).  There are also 
some VEGF-F forms which preferentially bind to VEGFR-1 (Takahashi et al. 2004, Chen et 
al. 2005).  
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2.3 SIGNAL TRANSDUCTION BY VEGF RECEPTORS AND CORECEPTORS 
2.3.1 Cell signaling by receptor tyrosine kinases (RTKs) 
The RTK family comprises 58 known transmembrane receptors in humans which are 
divided into 20 subfamilies, including the Epidermal growth factor receptor (EGFR) family, 
Insulin receptor (INSR) family, PDGFR family, Tie receptor family, Ephrin (Eph) receptor 
family, and VEGFR family. All RTKs have an extracellular ligand binding domain, ligand 
being usually a growth factor, a cytokine, or a hormone, a single transmembrane helix, and 
a cytoplasmic region containing a protein tyrosine kinase domain (TKD). In addition, RTKs 
might contain C-terminal and juxtamembrane regulatory regions. Extracellular regions 
contain conserved motifs, including immunoglobulin (Ig)-like or EGF-like domains, or 
fibronectin type III repeats (Blume-Jensen, Hunter 2001, Lemmon, Schlessinger 2010). RTKs 
are characterized by intrinsic ligand-induced tyrosine kinase activity. When ligand is not 
bound, RTKs exist in an inactive monomeric or, in some cases, oligomeric state, and the 
activity of TKD is repressed by autoinhibition of its activation loop (Figure 3). Upon ligand 
binding, the receptor becomes dimerized (or oligomerized), its conformation changes, and 
TKD transphosphorylates tyrosines in the neighboring RTK activation loop, in the 
juxtamembrane domain, or in the C-terminal region releasing the autoinhibition and fully 
activating the TKD. Subsequently, other tyrosine residues in the C-terminal domain of most 
RTKs can be autophosphorylated creating binding sites for intracellular enzymes and 
adaptor molecules having Src Homology 2 (SH2) or Phosphotyrosine-binding (PIB) 
domains, such as Src, phospholipase C-γ (PLCγ), and phosphatidylinositol-3 kinase (PI3K). 
More than one SH2- or PIB-containing molecules can associate with the activated RTK, 
allowing simultaneous activation of a complex network of signals that proceed inside the 
cell leading to multiple cellular responses, such as proliferation, differentiation, migration, 
and survival. One classical example, activated for example by EGF binding to EGFR, is the 
Grb2-SOS-Ras-Raf-MEK-MAP kinase pathway leading to cell proliferation. Activated RTKs 
are eventually internalized by ligand-stimulated endocytosis and either recycled to the 
plasma membrane or degraded. RTKs can also continue to activate intracellular signaling 
pathways after their internalization (Blume-Jensen, Hunter 2001, Lemmon, Schlessinger 
2010). 
Figure 3. RTK activation. After ligand binding and receptor dimerization, TKD autoinhibition is 
released and the phosphorylation of tyrosine residues takes place leading to the binding of 
intracellular signaling molecules. Modified from Blume-Jensen and Hunter (2001). 
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2.3.2 VEGFR-1 
VEGFR-1 is a receptor for VEGF-A, PlGF, VEGF-B, and some VEGF-F forms (de Vries et al. 
1992, Park et al. 1994, Olofsson et al. 1998, Takahashi et al. 2004, Chen et al. 2005). All VEGF 
receptors are composed of seven Ig-like domains in their extracellular part, and VEGFR-1 
ligands have been shown to bind to the second and third domain, thus cross-linking the 
receptor monomers (Davis-Smyth et al. 1996, Wiesmann et al. 1997, Christinger et al. 2004, 
Iyer, Darley & Acharya 2010). However, it has been shown that compared to the other 
ligands, VEGF-B does not require domain 3 for high-affinity binding (Anisimov et al. 
2013a). After ligand binding, membrane-proximal domains 4-7 make homotypic contacts 
stabilizing and activating VEGFR-1, and this is the case also in VEGFR-2 and -3 (Yang et al. 
2010b, Kisko et al. 2011, Anisimov et al. 2013a). VEGFR-1 has been shown to be 
indispensable for development of the vasculature, since the deletion of Vegfr1 leads to 
embryonic lethality at embryonic day (E) 8.5-9.0 due to excess endothelial cell proliferation 
(Fong et al. 1995). On the contrary, the deletion of the VEGFR-1 kinase domain does not 
disrupt normal development and angiogenesis (Hiratsuka et al. 1998). VEGF-A has a much 
greater affinity towards VEGFR-1 than VEGFR-2, although the kinase activity of VEGFR-1 
has been shown to be poor (Waltenberger et al. 1994). This implies a role of VEGFR-1 as an 
inactive decoy, controlling the availability of VEGF-A. A soluble form of the receptor, 
sVEGFR-1, lacking the transmembrane and intracellular parts also sequesters VEGF-A from 
the signaling receptors (Kendall, Thomas 1993). sVEGFR-1 is highly expressed in placenta, 
and its increased levels have been shown to be associated with pre-eclampsia (Vuorela et al. 
2000). The phosphorylated tyrosine (Tyr) residues of the VEGFR-1 intracellular domain are 
Tyr-794, Tyr-1169, Tyr-1213, Tyr-1242, Tyr-1309, Tyr-1327, and Tyr-1333 (Cunningham et al. 
1997, Ito et al. 1998). The phosphorylation pattern of Tyr-1309 has been shown to differ 
depending on the ligand used for VEGFR-1 activation (Autiero et al. 2003). Several 
signaling molecules, such as PLCγ, PI3K, Grb2, and Nck, have been shown to bind to 
phosphorylated tyrosine residues, but hardly any proliferative or migratory effects have 
been seen in endothelial cells (Figure 4) (Gille et al. 2001, Koch et al. 2011b). VEGFR-1 may 
also form heterodimers with VEGFR-2 and transphosphorylate VEGFR-2, thus regulating 
endothelial cell functions through VEGFR-2 activation (Huang et al. 2001, Autiero et al. 
2003). In addition to endothelial cells, VEGFR-1 is also expressed in monocytes and 
pericytes (Clauss et al. 1996, Witmer et al. 2002).  
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Figure 4. Signal transduction pathways downstream of VEGFR-1. Several signaling mediators, 
such as PLCγ, PI3K, Grb2, and Nck, bind to the phosphorylated Tyr-794, Tyr, 1169, and Tyr- 
1213, but their precise role in the activation of certain downstream signaling pathways in ECs is 
unclear. Tyr-1309 is phosphorylated only after PlGF binding. In ECs, the overall activity of 
VEGFR-1 is low, and it mainly functions as a ligand trap. VEGF-B seems not to activate the 
receptor. In monocytes, downstream signaling is induced more efficiently after VEGFR-1 
activation. 
2.3.3 VEGFR-2 
VEGFR-2 is considered to be the main receptor mediating VEGF-induced endothelial cell 
proliferation, migration, survival, and enhanced vascular permeability. It is likely that all 
VEGFR-2 ligands, VEGF-A, VEGF-C, VEGF-D, VEGF-E, and VEGF-F, bind to the same sites 
of the receptor, and in the case of VEGF-A, -C, and -E, these sites have been shown to be the 
Ig-like domains 2 and 3 (Leppanen et al. 2010, Brozzo et al. 2012). VEGFR-2 exists also as an 
alternatively spliced soluble form, and endogenous sVEGFR-2 has been shown to prevent 
VEGF-C binding to VEGFR-3, thus inhibiting lymphatic vessel growth (Albuquerque et al. 
2009). VEGFR-2 is indispensable during embryonic vasculogenesis and angiogenesis, and 
Vegfr2 deficient mice die at E8.5-9.5 due to the absence of endothelial or hematopoietic cells 
(Shalaby et al. 1995). Also, the deletion of the major phosphorylation site of VEGFR-2, Tyr-
1175, leads to embryonic lethality at E8.5-9.5 (Sakurai et al. 2005). Other major 
phosphorylation sites in VEGFR-2 have been shown to be Tyr-951 in the kinase insert 
domain, Tyr-1054 and Tyr-1059 within the kinase domain, and Tyr-1214 in the C-terminal 
domain (Dougher-Vermazen et al. 1994, Takahashi et al. 2001, Matsumoto et al. 2005). The 
autophosphorylation of Tyr-1054 and Tyr-1059 has been shown to be essential for the 
catalytic activity of the receptor kinase (Kendall et al. 1999). The major downstream 
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signaling pathways include PLCγ- and protein kinase C (PKC) - mediated activation of the 
mitogen-activated protein kinase (MAPK) pathway leading to Erk1/2 phosphorylation and 
subsequent cell proliferation (Takahashi et al. 2001), PI3K-mediated activation of Akt 
leading to cell survival (Gerber et al. 1998), and increased NO production via activated 
endothelial NO synthase (eNOS) leading to increased vascular permeability (Figure 5) 
(Dimmeler et al. 1999, Fulton et al. 1999). Src activation, in a VEGF/T-cell-specific adapter 
(TSAd) - dependent manner, has been shown to play a role on vascular permeability effect 
by modulating vascular endothelial (VE)-cadherin phosphorylation and internalization 
(Wallez et al. 2007, Sun et al. 2012). Also, actin reorganization and endothelial cell migration 
are regulated by Src activation (Matsumoto et al. 2005). In addition to Src, Focal adhesion 
kinase (FAK), p38MAPK, and Heat-shock protein 27 (Hsp27) have been shown to be 
involved in cell migration (Lamalice et al. 2004, Lamalice, Houle & Huot 2006, Evans, 
Britton & Zachary 2008). It is not clear whether the classic Ras-Raf-MEK-MAPK pathway 
plays a significant role in VEGFR-2 signaling. The VEGF-induced activation of the Raf-
MEK-MAPK pathway has been shown to be mediated by PLCγ and PKC, not via Grb2-
SOS-Ras (Takahashi, Ueno & Shibuya 1999). However, Ras is also shown to be activated 
downstream of VEGFR-2, and this may involve PKC-mediated activation of sphingosine 
kinase (SPK) (Shu et al. 2002).  
In unstimulated cells, VEGFR-2 is found both on the plasma membrane and in the 
recycling endosomes from where VEGFR-2 is delivered to the cell membrane upon VEGF-
stimulation (Gampel et al. 2006, Ballmer-Hofer et al. 2011). VEGFR-2 activation is regulated 
by clathrin-dependent endocytosis, endosomal sorting, and subsequent receptor 
degradation in lysosomes and proteasomes (Ewan et al. 2006, Ballmer-Hofer et al. 2011). 
Internalized VEGFR-2 may also be recycled back to the plasma membrane where it is again 
able to bind to its ligands (Ballmer-Hofer et al. 2011). VEGFR-2 tyrosine phosphorylation 
and downstream signaling are also continued from endosomes, and for example Erk1/2 has 
been shown to be activated by the internalized VEGFR-2 (Lampugnani et al. 2006).  
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Figure 5. Signal transduction pathways downstream of VEGFR-2. Phosphorylated Tyr-951, Tyr-
1214, and Tyr-1175 are bound by signaling mediators, such as TSAd, Nck, PLCγ, and Shb, 
activating multiple signaling cascades leading to EC proliferation, migration, survival, and 
vascular permeability. See the main text for details. 
2.3.4 VEGFR-3 
VEGFR-3 is the main receptor mediating lymphangiogenesis. Both full-length and mature 
forms of VEGF-C and -D bind to VEGFR-3, and in addition to domains 2 and 3, domain 1 of 
the receptor has been shown to be required for ligand binding (Joukov et al. 1997, Stacker et 
al. 1999a, Leppanen et al. 2013). VEGFR-3 is proteolytically cleaved at domain 5 during its 
maturation (Leppanen et al. 2013). At the early developmental stage, VEGFR-3 is expressed 
in vascular endothelial cells, but later, the expression is most prominent in lymphatic 
vascular endothelium (Kaipainen et al. 1995, Kukk et al. 1996). Mouse knockout studies 
have shown that the receptor is necessary for blood vascular development, since mice 
devoid of Vegfr3 die at E9.5 due to defects in the remodeling of primary vascular networks 
(Dumont et al. 1998). VEGFR-3 has been shown to induce migration, proliferation, and 
survival of lymphatic endothelial cells after phosphorylation of its major tyrosine residues 
Tyr-1230, Tyr-1231, Tyr-1265, Tyr-1337, and Tyr-1363 in the receptor C-terminal domain 
(Dixelius et al. 2003). In addition, Tyr-1068 phosphorylation is required for receptor kinase 
activity and Tyr-1063 phosphorylation for survival signals (Salameh et al. 2005). Two main 
signaling pathways have been well-characterized, namely PKC-mediated activation of 
Erk1/2 and PI3K-mediated activation of Akt (Figure 6) (Makinen et al. 2001, Salameh et al. 
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2005). It has also been shown that some ligand-dependent cellular events depend on 
VEGFR-2/VEGFR-3 heterodimerization, and when complexed with VEGFR-2, only some of 
the VEGFR-3 tyrosine residues become phosphorylated (Dixelius et al. 2003, Alam et al. 
2004). In addition to inducing lymphangiogenesis, VEGFR-3 has been shown to regulate 
angiogenic sprouting by modulating Notch signaling (Tammela et al. 2008, Tammela et al. 
2011). 
 
 
 
Figure 6. Signal transduction pathways downstream of VEGFR-3. After VEGFR-3 activation, at 
least the signaling mediator Grb2 binds to the phosphorylated Tyr-1230 and Tyr-1231. Erk1/2 
and Akt are activated in lymphatic ECs leading to cell proliferation, migration, and survival. 
VEGFR-3 is also activated in blood ECs at the sites of active angiogenesis. 
2.3.5 Coreceptors Nrp-1, Nrp-2, HSPGs, and Integrins 
Nrp-1 and Nrp-2 are transmembrane proteins with a cytoplasmic domain lacking intrinsic 
catalytic activity. Nrps share 44 % homology with each other. They were first identified in 
the nervous system as receptors for class 3 semaphorins (SEMA3) (He, Tessier-Lavigne 
1997, Kitsukawa et al. 1997). Later, Nrp-1 was found to bind to VEGF-A (Soker et al. 1996, 
Soker et al. 1998). The b1-domain of Nrp-1 has been shown to mediate the high-affinity 
binding to VEGF-A with some contribution of the b2 domain (Gu et al. 2002, Parker et al. 
2012). Nrp domains a1/a2 and b1/b2 are crucial for SEMA3A binding (Gu et al. 2002). The 
C-terminal E8a-encoded six amino acids of VEGF-A have been shown to be primarily 
responsible for binding to Nrp-1, and E5 and/or E7 may either stabilize these interactions or 
form a bridge between Nrp-1 and VEGFR-2 (Pan et al. 2007b, Parker et al. 2012, Delcombel 
et al. 2013). Nrp-1 acts as a coreceptor for VEGFR-1 and -2 thereby modulating their 
angiogenesis-mediating effects (Soker et al. 1998, Soker et al. 2002). The importance of Nrp-
15 
 
 
1 is highlighted by the fact that the deletion of Nrp1 leads to embryonic lethality at day 
E12.5-13.5 due to neuronal and cardiovascular defects (Kitsukawa et al. 1997, Kawasaki et 
al. 1999). Interestingly, recent studies indicate that VEGF-A binding to Nrp-1 does not have 
a major role in embryonic angiogenesis, but postnatally, the lack of this interaction results 
in reduced retinal vascularization, and decreased pathophysiological angiogenesis (Fantin 
et al. 2014). Nrp-2, on the other hand, is mainly a coreceptor for VEGFR-3 modulating its 
lymphangiogenic function (Karpanen et al. 2006). Nrp2 knockout mice are viable but 
display abnormal development of small lymphatic vessels and capillaries as well as mild 
neuronal anomalies (Giger et al. 2000, Yuan et al. 2002). However, mice lacking both Nrp1 
and Nrp2 have defects in vasculogenesis and die at E8.5 (Takashima et al. 2002). The precise 
role of Nrp-1 in VEGF-mediated signaling is not clear, but Nrp-1 has been shown to form 
complexes with VEGF/VEGFR-2 thereby stabilizing the binding of VEGFs to VEGFR-2 
(Soker et al. 2002). Nrp-1 is not required for the activation of either VEGFR-2 or the major 
downstream signaling molecules Erk1/2 or Akt (Kawamura et al. 2008), but binding to both 
Nrp-1 and VEGFR-2 has been shown to increase VEGF-induced endothelial cell migration, 
sprouting, and branching (Pan et al. 2007b, Kawamura et al. 2008, Evans et al. 2011, Herzog 
et al. 2011). In addition, Nrp-1 has been shown to promote VEGFR-2 vesicular trafficking 
inside the cell leading to the activation of specific signaling molecules (Ballmer-Hofer et al. 
2011). VEGF binding to Nrp-1 might also activate signaling cascades independently of 
VEGFR-2 leading to enhanced migration (Wang et al. 2003, Wang, Mukhopadhyay & Xu 
2006). 
HSPGs are components of the cell surface and ECM. HSPGs bind to several VEGFs 
thereby sequestering them at the cell surface and aiding and stabilizing the binding of 
VEGFs to their receptors (Gitay-Goren et al. 1992, Dougher et al. 1997). HSPGs also function 
as reservoirs for growth factors and participate to the formation of concentration gradients 
to allow blood vessel branching (Ruhrberg et al. 2002). In addition to VEGFs, HSPGs also 
bind to VEGFR-1 and -2 as well as Nrp-1 and participate in VEGF/VEGFR/Nrp complex 
formation and stabilization (Dougher et al. 1997, Park, Lee 1999, Mamluk et al. 2002).  
Integrins are transmembrane proteins that connect cell cytoskeleton to ECM 
components. Different integrins have been shown to form complexes with VEGFR-2 in a 
VEGF-dependent manner and modulate VEGFR-2 activation and signaling 
(Mahabeleshwar et al. 2008, Chen et al. 2010). In addition, VEGF-induced integrin binding 
to Nrp-1 has been shown to sequester Nrp-1 and prevent its interaction with VEGFR-2 
(Robinson et al. 2009). 
2.4 NEURONAL GUIDANCE MOLECULES IN ANGIOGENESIS 
Several neuronal guidance molecules have been shown to regulate the proper formation of 
closely situated nerves and blood vessels. This is due to the anatomical and functional 
similarities between axonal growth cones and specialized endothelial cells, called tip cells, 
at the leading edge of a sprouting capillary (Adams, Eichmann 2010). Axonal growth cones 
and endothelial tip cells respond to same guidance cues from the environment and the 
same molecule can mediate either repellent or attractive signals, depending on the 
situation. These guidance molecules include Ephrins and Eph receptors, Netrins and 
Uncoordinated-5 (UNC5) receptors, Slits and Robo receptors, and Semaphorins and their 
receptors Plexins and Nrps. In the vasculature, these neuronal guidance molecules regulate 
vascular remodeling and vessel navigation and, thus, have an important role in angiogenic 
processes (Klagsbrun, Eichmann 2005, Adams, Eichmann 2010). 
2.4.1 Slits and Robos 
Slits and their Robo receptors are recently identified regulators of vascular remodeling. 
They were first identified in Drosophila neurons with repellent functions in axonal 
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guidance and neuronal migration (Brose et al. 1999, Li et al. 1999). Later, these neuronal 
guidance molecules were found in mammals, and their expression was also detected in 
nonneuronal cells, for example in leucocytes and endothelial cells (Wu et al. 2001, Wong et 
al. 2002, Huminiecki et al. 2002, Park et al. 2003). There are three Slit proteins (Slit1-3) and 
four Robo receptors (Robo1-4) in mammals (Itoh et al. 1998, Kidd et al. 1998, Huminiecki et 
al. 2002, Park et al. 2003). The fourth member of the Robo-family, Robo4/Magic roundabout, 
is exclusively expressed in vascular endothelium (Huminiecki et al. 2002). Also, Slit2, Slit3, 
and Robo1 are expressed in vascular endothelial cells (Zhang et al. 2009). Slits are 
composed of four leucine-rich repeat (LRR) domains, EGF-like repeats, a laminin-G-like 
domain, and a C-terminal cysteine knot (Rothberg, Artavanis-Tsakonas 1992). Slits are 
proteolytically processed to N- and C-terminal fragments, which may have different 
biological functions (Wang et al. 1999, Nguyen Ba-Charvet et al. 2001). Slit dimerization, 
mediated by the fourth LRR-domain, might be required for some of its functions (Howitt, 
Clout & Hohenester 2004). Robo proteins belong to the Ig-superfamily consisting of five Ig-
like domains, three fibronectin type III repeats, a transmembrane portion, and a long 
intracellular tail containing up to four conserved cytoplasmic motifs, CC0-CC3. Robo4 
differs structurally from other Robos by having only two Ig-like domains and two 
fibronectin repeats, and it has only the motifs CCO and CC2 in its C-terminus (Figure 7) 
(Huminiecki et al. 2002, Morlot et al. 2007). It has been shown that the interacting domains 
of Slit1-3 and Robo1-3 are the second LRR domain and the first two Ig-like domains, 
respectively (Howitt, Clout & Hohenester 2004, Morlot et al. 2007). The two Ig-like domains 
of Robo4 are most similar to the first two Ig-like domains of Robo1, but Robo4 does not 
have the same key residues shown to be required for Slit binding in the case of Robo1 
(Morlot et al. 2007). The interaction between Slits and Robos may also include HSPG 
syndecans, which could act as coreceptors or stabilize Slit/Robo complexes (Steigemann et 
al. 2004). 
 
                           
Figure 7. Different vertebrate Robo-receptors and receptor binding profiles of Slits.  
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2.4.2 Slit-Robo signaling  
In Drosophila neurons, Abelson tyrosine kinase (Abl) and Enabled (Ena) have been shown 
to mediate cytoskeletal remodeling downstream of Slit-Robo. Abl phosphorylates the CC0 
and CC1 motifs in Robo, leading to its inactivation, and CC2 was shown to be the binding 
site for Enabled (Ena) which mediates repulsive signaling (Bashaw et al. 2000). In addition, 
the motif CC3 has been shown to interact with Rho GTPase activating proteins (GAPs) 
which control the activity of small Rho GTPases, particularly RhoA, Rac1, and Cdc42, 
leading to changes in actin cytoskeleton, cell migration, and axonal growth (Wong et al. 
2001, Etienne-Manneville, Hall 2002).  
The role of Slit-Robo signaling in the vasculature seems to be complex, and there have 
been contradictory reports about the outcome of Slit-Robo signaling. Slit2 binding to Robo1 
has been shown to induce endothelial cell migration and tube formation as well as 
lymphangiogesis and tumor metastasis (Wang et al. 2003, Sheldon et al. 2009, Yang et al. 
2010a). Robo4 has been shown to mediate both pro- and anti-angiogenic signals (Park et al. 
2003, Kaur et al. 2006, Sheldon et al. 2009). Several reports have indicated that Slit2-
dependent activation of Robo4 would restrain VEGF-induced angiogenesis and vascular 
permeability by inhibiting Src, FAK, small GTPases, such as Rac1 and Arf6, as well as by 
modulating VE-cadherin localization in order to enhance vascular stability (Figure 8) (Jones 
et al. 2008, Jones et al. 2009, London et al. 2010, Marlow et al. 2010). Recently, Slit2 was also 
shown to inhibit VEGF-C-induced lymphatic endothelial cell proliferation, migration, and 
tube formation via Robo4 (Yu et al. 2014). However, it is still under debate if Slit2 can 
actually bind to Robo4, since Slit2-Robo4 interaction has only been detected using 
immunoprecipitation, but not using surface plasmon resonance assay (Park et al. 2003, 
Suchting et al. 2005). Nevertheless, Robo4 may form a complex with Robo1, where Robo1 
would be the ligand binding receptor and Robo4 the signaling receptor (Sheldon et al. 
2009). Also, a model has been postulated, where Slit2, as a single agent, promotes 
angiogenesis, but in the presence of Ephrin-A1, Slit2 inhibits angiogenesis (Dunaway et al. 
2011). In addition to Slit2, also Slit3 functions in the vasculature, and it has been shown to 
induce angiogenesis through Robo4 (Zhang et al. 2009). Robo4 has also been shown to be 
activated by other ligands besides Slits, such as the vascular-specific axon guidance 
receptor UNC5B, and to inhibit VEGF-mediated angiogenesis and permeability (Koch et al. 
2011a).  
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Figure 8. The suggested Slit2-mediated signal transduction pathways downstream of Robo1 and 
Robo4 in endothelial cells. Slit2-Robo1 signaling leads to enhanced angiogenic effects at least 
through PI3K activation. Instead, Slit2-Robo4 signaling blocks VEGF-VEGFR-2-induced 
activation of Src, Arf6, Rac1, and FAK leading to reduced angiogenic effects. Robo1 and Robo4 
may also form heterodimers, or some so far undefined coreceptors might be present as well. 
2.5 VEGF-BASED THERAPIES IN VASCULAR DISEASES 
2.5.1 Cardiovascular diseases  
Cardiovascular diseases are the leading cause of death globally. The most common risk 
factors for cardiovascular diseases include smoking, high blood pressure, high blood 
cholesterol, unhealthy diet, obesity, physical inactivity, and diabetes (Perk et al. 2012). 
Cardiovascular diseases such as CAD, and its clinical manifestations angina, myocardial 
infarction, and stroke, and PAD usually result from an atherosclerotic process. In 
atherosclerosis, the lumen of an artery is narrowed thereby restricting blood flow. This 
leads to reduced transport of nutrients and oxygen to tissues and the formation of ischemic 
areas. In CAD, atherosclerosis affects the coronary arteries in the heart. In PAD, the affected 
arteries carry blood to the limbs. CAD and PAD are treated noninvasively with lifestyle 
changes and different drugs and invasively with balloon angioplasty and stenting or 
bypass surgery (Perk et al. 2012, Halonen et al. 2014). 
2.5.1.1 Atherosclerosis  
Atherosclerosis is a chronic inflammatory state of the arterial wall. Atherosclerosis is 
characterized by low-density lipoprotein (LDL) accumulation in the subendothelial space 
where LDL is oxidized and taken up by infiltrated macrophages. Macrophages turn into 
foam cells and fatty streaks start to form under the arterial endothelium. SMCs start to 
migrate from the medial layer into the subendothelial space (intima), proliferate, and 
secrete extracellular matrix proteins, and developed plaques increase in size. When foam 
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cells and SMCs die, a lipid-rich necrotic core is formed (Lusis 2000, Glass, Witztum 2001). 
Advanced plaques are characterized by a fibrous cap, foam cells, a large necrotic core, 
calcification, and formation and sprouting of microvessels. Vulnerable plaques are prone to 
rupture leading to the formation of thrombus and acutely occluded arteries. Narrowing of 
the vessel lumen can lead to ischemic symptoms, such as chest pain or numbness in legs. 
Plaque rupture and thrombosis are the main reasons for the acute cardiovascular events 
like myocardial infarction and stroke (Lusis 2000, Glass, Witztum 2001, Yla-Herttuala et al. 
2013).  
Pro-angiogenic molecules, such as VEGFs, are expressed by activated inflammatory cells, 
endothelial cells, and SMCs in atherosclerotic lesions (Vuorio, Jauhiainen & Yla-Herttuala 
2012). Hypoxia, due to thickening of the arterial wall, seems to be the main mediator of 
intraplaque neovascularization, which may contribute to plaque instability and rupture. 
Microvessels have been shown to originate from the adventitia extending through media 
into the plaque, and VEGFs may contribute to their sprouting. These microvessels are 
disorganized, enlarged, and leaky. VEGFs may also enhance SMC migration and 
production of inflammatory cytokines in atherosclerotic lesions. Anti-angiogenic strategies 
have been tested in pre-clinical studies for restraining plaque progression. These include 
the use of an anti-VEGFR-1 antibody and a plasmid expressing sVEGFR-1 as well as 
VEGFR-2 vaccination (Vuorio, Jauhiainen & Yla-Herttuala 2012). However, pro-angiogenic 
therapies can be considered for the treatment of diseases that result from atherosclerosis, 
CAD and PAD, and this issue will be discussed in the following chapter.  
2.5.1.2 Pro-angiogenic therapies for CAD and PAD 
Not all CAD and PAD patients are suitable for treatment with conventional 
revascularization strategies, and therefore, delivery of angiogenic genes or recombinant 
proteins into ischemic tissues has offered a way to induce angiogenesis and arteriogenesis. 
Several pre-clinical and clinical trials have been conducted with different VEGFs or other 
angiogenic molecules, and this has led to improved blood flow in the hypoxic or ischemic 
area (Table 1) (Giacca, Zacchigna 2012, Halonen et al. 2014). Also, there have been no signs 
of increased risk of atherosclerosis in humans after pro-angiogenic therapies (Vuorio, 
Jauhiainen & Yla-Herttuala 2012). However, the efficacy of pro-angiogenic therapies in 
clinical trials has not met the expectations from the results of the preclinical work, and 
several reasons, like insufficient therapeutic dose, relatively low vector transduction 
efficiency, inadequate duration of exposure, and patient-related issues, have been 
suggested for explanation (Zachary, Morgan 2011, Dragneva, Korpisalo & Yla-Herttuala 
2013). Also, better animal models have to be developed to mimic human disease states 
(Dragneva, Korpisalo & Yla-Herttuala 2013).  
The major side-effects of VEGF gene therapy are the increased vascular permeability in a 
VEGF dose-dependent manner and the subsequent accumulation of fluid and edema in 
tissues (Vajanto et al. 2002, Rajagopalan et al. 2003, Korpisalo et al. 2011). Several attempts 
have been made to improve the outcomes of pro-angiogenic therapies. Lower doses of 
VEGFs have been shown to decrease the side-effects, but unfortunately, also the beneficial 
therapeutic effects were lost (Korpisalo et al. 2011). Chimeric VEGF forms have been 
designed for reduced vessel leakiness by combining VEGF-A VHD region with the N- and 
C-terminal propeptides of VEGF-C or with the receptor binding part of Ang-1 (Keskitalo et 
al. 2007, Anisimov et al. 2013b). Also, VEGF gene transfers have been performed in 
combination with Ang-1 to produce more mature vessels (Chen et al. 2007, Su et al. 2009).  
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Table 1. Completed or ongoing pro-angiogenic clinical trials. Modified from Zachary and Morgan 
(2011), Vuorio, Jauhiainen and Yla-Herttuala (2012), and Halonen et al. (2014). 
 
 
 
Delivery Gene Disease Result Reference/Source 
Recombinant protein VEGF-A165 CAD Negative Henry et al. 2003 
FGF-2 PAD Positive Lederman et al. 2002 
CAD Negative Simons et al. 2002 
GM-CSF CAD Positive Seiler et al. 2001 
Plasmid DNA VEGF-A165 CAD Negative Stewart et al. 2009 
  PAD Negative Kusumanto et al. 2006 
 VEGF-A165/FGF-2 CAD Negative Kukula et al. 2011 
 
VEGF-C CAD Negative http://medicalnewstoday.com/rele
ases/53786.php 
 HGF PAD Negative Powell et al. 2008 
 FGF-1 PAD Negative Nikol et al. 2008 
 Del-1 PAD Negative Grossman et al. 2007 
Adenovirus VEGF-A165 CAD Positive Hedman et al. 2003 
  PAD Positive Makinen et al. 2002 
 VEGF-A121 CAD Positive Stewart et al. 2006 
  PAD Negative Rajagopalan et al. 2003 
 
VEGF-DΔNΔC CAD Ongoing http://clinicaltrials.gov/show/NCT0
1002430 
 
 PAD Ongoing https://www.clinicaltrialsregister.e
u/ctr-search/search?query=2012-
001019-22 
 FGF-4 CAD Negative Henry et al. 2007 
 HIF-1/VP16 PAD Negative Creager et al. 2011 
 
VEGF-AII6A+ CAD Ongoing http://clinicaltrials.gov/show/NCT0
1757223 
Retrovirus Ang-1/VEGF-A165 PAD Ongoing http://clinicaltrials.gov/show/NCT0
0956332 
Ang, angiopoietin; CAD, coronary artery disease; Del-1, developmentally regulated endothelial locus 1; 
FGF, fibroblast growth factor; HGF, hepatocyte growth factor; HIF, hypoxia inducible factor; PAD, 
peripheral artery disease; VEGF, vascular endothelial growth factor 
2.5.2 Cancer 
VEGF-A plays an essential role in tumor formation, progression, and metastasis. Tumors 
are not able to grow beyond a certain size without new blood vessel formation to support 
their nutrient and oxygen needs. Tumor cells constantly secrete several angiogenic factors, 
such as VEGF-A and FGF-2, and due to the uncontrolled endothelial cell stimulation, the 
newly-formed blood vessels are not maturated but are disorganized, morphologically 
abnormal, and leaky (Carmeliet, Jain 2000). The increased vascular permeability leads to 
edema formation and may also increase metastatic spread of tumors via blood vessels 
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(Criscuoli, Nguyen & Eliceiri 2005). The main reason for the overproduction of VEGF-A is 
hypoxia due to poor blood perfusion and elevated interstitial fluid pressure inside the 
tumor vessels. Constant VEGF-A production also induces the upregulation of matrix 
metalloproteinases leading to increased tumor invasiveness (Munaut et al. 2003). In 
addition, VEGF-A inhibits functions of the immune system by reducing dendritic cell (DC) 
population as well as inhibiting T-cell development (Ohm, Carbone 2002). Lymphatic 
vessel growth, induced by VEGF-C and VEGF-D via VEGFR-3, is also increased near 
tumors, and the metastatic spread of tumors often occurs via lymphatic vessels to the 
lymph nodes (Achen, Stacker 2008). Also, the expression of Nrp-1 and Nrp-2 is upregulated 
in many types of tumors, but the precise role of neuropilins in tumorigenesis is unclear 
(Pellet-Many et al. 2008). Although many studies imply neuropilins to be pro-tumorigenic, 
there are also some controversial results (Ellis 2006).  
Several anti-angiogenic and anti-lymphangiogenic strategies have been developed to 
inhibit tumor growth and metastatic spread, and some treatments are already used in the 
clinics (Tugues et al. 2011, Stacker et al. 2014). Examples include antibodies against VEGFs 
and their receptors, sVEGFRs that inhibit ligand binding to signaling receptors, and small 
molecule tyrosine kinase inhibitors (TKIs) competing for adenosine triphosphate (ATP) - 
binding to the VEGFR intracellular kinase domain (Tugues et al. 2011, Stacker et al. 2014). 
2.5.3 Other conditions 
VEGFs also have a role in other diseases, such as in retinopathies, lymphedema, psoriasis 
and rheumatoid arthritis (RA). In wet age-related macular degeneration (wAMD), VEGF-A 
induces choroidal neovascularization through the Bruch’s membrane into the retina leading 
to fluid leakage and edema due to immature blood vessels, bleeding under the retina, and 
eventually blindness unless treated properly (Cheung, Eaton 2013, Miller et al. 2013). 
Diabetic retinopathy is another leading cause of blindness in the developed world. Diabetes 
leads to endothelial dysfunction and subsequent loss of retinal endothelial cells leading to 
ischemia. Hypoxia upregulates the production of VEGF-A resulting in intraretinal 
neovascularization characterized by leaky vessels, edema, and impairment of the vision. In 
an advanced complication of diabetic retinopathy, diabetic macular edema, swelling of the 
central retina causes loss of central vision (Boyer et al. 2013, Miller et al. 2013). Anti-VEGF 
therapies have been used to treat wAMD and diabetic retinopathy (Boyer et al. 2013, 
Cheung, Eaton 2013).  
Lymphedema results from the abnormal function of the lymphatic system. This leads to 
interstitial fluid accumulation and tissue swelling. In addition, lymphedema results in 
impaired immunity and fat accumulation (Jussila, Alitalo 2002, Harvey et al. 2005). 
Lymphedema can be genetically inherited, for example due to mutations in VEGFR-3, or it 
may be acquired after infection. Lymphatic filariasis (elephantiasis), an infectious disease 
caused by filarial nematodes in the tropical area, leads to inflammatory reaction, 
overproduction of VEGFs, and, subsequently, hyperplasia and damage of lymphatic vessels 
(Pfarr et al. 2009). Lymphedema is also frequently caused by lymph node removal and 
radiotherapy in cancer patients. In animal models, lymphangogenic growth factors, VEGF-
C and VEGF-D, have successfully been used to stimulate the growth of new lymphatic 
capillaries resulting in reduced edema (Szuba et al. 2002, Saaristo et al. 2004, Tammela et al. 
2007). Also, VEGF-C and VEGF-D administrations have been combined with lymph node 
transplantation increasing its success rate (Tammela et al. 2007, Lahteenvuo et al. 2011, 
Honkonen et al. 2013). 
Psoriasis and RA are complex autoimmune diseases where VEGF-A production is 
increased in skin lesions of psoriasis and by synovium fibroblasts in RA (Detmar et al. 1994, 
Szekanecz et al. 2010). In addition, increased serum VEGF-A levels have been shown to 
correlate with the disease state.  
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2.6 GENE THERAPY AND GENE TRANSFER VECTORS 
2.6.1 Basic concepts of human gene therapy 
Gene therapy can be described as transfer of nucleic acids into patients in order to treat 
acquired or inherited diseases (Verma, Weitzman 2005). With gene therapy, mutated gene 
causing a disease can be replaced with a healthy copy, mutated gene can be inactivated, or 
new therapeutic gene can be introduced into the body. Gene therapy can be divided into 
somatic gene therapy and germ line gene therapy. In somatic gene therapy, only the cells of 
the actual patient are affected and treatment is not passed on future generations. Germ line 
gene therapy results in permanent changes that are passed to offspring. Only somatic gene 
therapy is currently allowed and it is split into ex vivo and in vivo gene therapy methods. In 
ex vivo gene therapy approach, cells are modified outside the patient’s body and returned 
back to the patient. In in vivo gene therapy, gene delivery is performed in the patient’s 
body.  
The most efficient method of gene transfer is viral delivery, but also non-viral methods, 
such as injection of naked plasmid DNA, have been used (Verma, Weitzman 2005). More 
than 2000 gene therapy clinical trials were completed, ongoing, or approved worldwide by 
June 2014. Cancer is the most common disease treated with gene therapy followed by 
monogenic and cardiovascular diseases. However, gene therapy has been most promising 
in the treatment of diseases caused by single gene defects. Adenoviral vectors, retroviral 
vectors, and naked plasmids have been the most commonly used gene transfer vectors in 
clinical trials (Figure 9) (Ginn et al. 2013). The first Food and Drug Administration (FDA) - 
approved gene therapy clinical trial was done already in the year 1990 for the treatment of 
adenosine deaminase-deficiency (Blaese et al. 1995). In 2012, Glybera became the first gene 
therapy drug approved for clinical use in the Western world by the European Commission 
for the treatment of lipoprotein lipase deficiency (Kastelein, Ross & Hayden 2013).  
 
Figure 9. Vectors used in gene therapy clinical trials 2014. Source: The Journal of Gene 
Medicine, Wiley and Sons (http://www.abedia.com/wiley/index.html). 
2.6.2 Adenoviral vectors 
Adenovirus infection is a common cause for upper respiratory tract infection. There are 
over 50 different serotypes of adenoviruses capable to infect and replicate in several organs. 
Adenoviruses are icosahedral particles consisting of a non-enveloped protein capsid 
surrounding a protein core that contains a double-stranded (ds) linear DNA genome of 36 
kilobases (kb) in size (Kootstra, Verma 2003). The genome contains early (E1A, E1B, E2, E3, 
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E4) and late genes (L1-L5). Adenovirus capsid contains three major proteins: hexon, penton 
base, and fibers with knob domains. Knob domains have been shown to interact with cell 
surface receptors, namely Coxsackie-adenovirus receptor (CAR) (Bergelson et al. 1997). In 
addition, viral entry requires the interaction between the viral penton base and cellular 
integrins (Wickham et al. 1993). After the clathrin-mediated endocytosis, adenovirus 
escapes from the endosome and the viral DNA is transported to the nucleus through the 
nuclear pore for DNA replication and transcription. Adenovirus does not integrate into the 
host cell’s genome, but instead, the dsDNA stays in episomal form. The newly-formed 
virions are released to the surroundings after cell lysis (Kootstra, Verma 2003). 
Adenoviral vectors are the most commonly used gene transfer vehicles. They can 
transduce both dividing and non-dividing cells and transduction is transient, gene 
expression lasting typically two weeks (Kootstra, Verma 2003). The most common 
adenoviral vector serotype for therapeutic gene delivery is Ad5. First generation adenoviral 
vectors were generated by deleting the viral early transcription genes E1 and/or E3 to make 
space for transgenes up to 6,5-8,3 kb in size. E1 deletion makes the vector replication-
deficient in most cell lines. Nevertheless, E1-deleted vectors can be efficiently produced in 
E1 region complementing cell lines, such as 293 (Graham et al. 1977, Kootstra, Verma 2003).  
Due to the viral protein production, adenoviral vectors elicit cellular and humoral 
immune responses (Kafri et al. 1998). This leads to clearance of the transduced cells and 
reduces efficacy of the vector re-administration. Adenoviral vectors also activate innate 
immune response and cytokine production. For reducing immunogenicity, E2 and/or E4 
regions have also been deleted from adenoviral vectors. This increases further the cloning 
capacity, but vector production requires the use of additional complementing cell lines. So-
called gutless vectors have also been developed that do not contain any viral genes. To 
increase cellular tropism, modifications can be made to the fiber and penton base and 
different adenoviral vector serotypes can be used (Kootstra, Verma 2003). In clinical trials, 
the safety profile of adenoviral vectors has been very good (Hedman et al. 2009, Muona et 
al. 2012). The only unfortunate exception is the incident of Jesse Gelsinger, who died after 
an overdose of adenoviral gene transfer due to a massive immune response leading to 
organ failure and brain death (Wilson 2010).   
2.6.3 Baculoviral vectors and recombinant protein production  
Baculoviruses are large insect-specific viruses. They have a circular dsDNA genome of 
approximately 80-180 kb in size inside a protein capsid surrounded by an envelope (Miller 
1997). Baculoviruses can be divided into nucleopolyhedroviruses (NPV) and 
granuloviruses (GV). Autographa californica multiple nucleopolyhedrovirus (AcMNPV) is 
the best characterized baculovirus with a fully-sequenced genome (Ayres et al. 1994).  
AcMNPV exists naturally in two forms: occlusion-derived virus (ODV) and budded virus 
(BV). ODV is responsible for the primary infection as well as spreading the infection 
between insect hosts. BV spreads the infection within the insect host. ODV derives its 
envelope from the nuclear membrane of the insect cell, but the BV envelope is acquired 
from the host cell membrane (Federici 1997). The budded form of AcMNPV is able to 
transduce many types of dividing and non-dividing mammalian cells. It binds to cell 
surface HSPGs, more precisely syndecan-1, and enters the cell via endocytosis (Makkonen 
et al. 2013). The envelope glycoprotein (gp) 64 has a major role in the attachment of the 
virus to the cell surface.  
Nowadays, the generation of recombinant baculoviruses is fast (Luckow et al. 1993, 
Airenne et al. 2011). The method relies on bacterial transposition reaction called the Bac-To-
Bac (Invitrogen), and it has been further improved allowing efficient baculovirus 
generation (Airenne et al. 2003, Laitinen et al. 2005). AcMNPV is able to carry large 
transgene inserts, and gene expression is transient. Baculoviruses are not able to replicate 
outside insect hosts, which makes them safe gene transfer vectors. Although baculoviruses 
do not suffer from any pre-existing immunity in humans, the virus is quickly inactivated by 
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the serum complement system (Hofmann et al. 1995, Airenne et al. 2010). Baculovirus 
system has also been widely used for biotechnology applications, such as recombinant 
protein production (Kost, Condreay & Jarvis 2005). Recombinant proteins have been 
traditionally produced in baculovirus-infected insect cells, but due to modifications of the 
expression cassette, baculoviruses can also be used for gene expression and protein 
production in mammalian cells. The most frequently used insect cells for recombinant 
protein production are derived from Spodoptera frugiperda (Sf9 and Sf21AE) and 
Trichoplusia ni (BtI-Tn-5B1-4) (Ikonomou, Schneider & Agathos 2003). Insect cells have 
most of the post-translational protein processing capabilities, but glycosylation in insect 
cells differs in some aspects from glycosylation in mammalian cells (Kost, Condreay & 
Jarvis 2005). Baculovirus expression system has also been used for production of virus-like 
particles (VLPs) for vaccination. Examples include FDA- and European Medicines Agency 
(EMA) - accepted human vaccines for influenza H5N1 (FluBlok®) and papilloma virus and 
cervical cancer (Cervarix®) (Lin, Chen & Hu 2011).  
2.6.4 Other viral and non-viral vectors  
Unlike adenoviruses and baculoviruses, adeno-associated viruses (AAV) and retroviruses 
can integrate their genomes as part of the host cell genome. AAVs are small non-pathogenic 
viruses, which require a helper virus in order to propagate. AAV does not have an 
envelope surrounding its single-stranded (ss) linear DNA genome of 4,7 kb in size. The 
genome contains rep and cap genes encoding regulatory and structural proteins, 
respectively. Virus enters the cells via endocytosis, and the ssDNA is transported to the 
nucleus where it is made double-stranded. In the absence of a helper virus, wild type AAV 
integrates its dsDNA into a specific location of the host cell chromosome 19 by homologous 
recombination (Kootstra, Verma 2003). AAV serotype 2 (AAV-2) is commonly used for 
gene transfer purposes. In the most advanced vector production system, AAV vector 
contains only a promoter and a transgene, packaging construct provides the rep and cap 
genes, adenoviral helper construct provides genes essential for transgene production, and 
complementing cell line provides the E1 area needed for replication (Kootstra, Verma 2003, 
Wu, Asokan & Samulski 2006). Different AAV vector serotypes have distinct tropism due to 
binding to different cell surface receptors. AAV vector dsDNA genome can persist in 
transduced cells for a long time. Integration of a transgene happens with a very low 
frequency with replication deficient AAV vector, and it is mostly expressed episomaly. 
Disadvantages of AAV vectors are their limited transgene capacity and a strong humoral 
immune response against the viral capsid (Brockstedt et al. 1999, Wu, Asokan & Samulski 
2006). 
Retroviruses are enveloped RNA viruses with two copies of the viral RNA genome 
inside a protein core. There are three essential genes, gag, pol, and env, in the RNA genome. 
After cell entry through endocytosis, retroviral RNA genome is reverse transcribed into 
dsDNA and transported to the nucleus where it is integrated randomly into the host cell 
genome (Nisole, Saib 2004, Verma, Weitzman 2005). Replication-deficient retroviral vectors 
have been developed by replacing all viral genes with promoter-derived transgenes and the 
viral genes are provided in trans in packaging cells. Oncoretroviral vectors, such as murine 
leukemia virus (MLV) – based vectors, can transduce only dividing cells, but lentiviruses 
can transduce both dividing and non-dividing cells. Retroviral vectors can be pseudotyped 
with different glycoproteins to extend cellular tropism (Verma, Weitzman 2005). 
Unfortunately, the random integration of transgenes can cause insertional mutagenesis if 
the integrated gene interferes with tumor suppressor gene or activates an oncogene 
(Cavazza, Moiani & Mavilio 2013). Retroviral vectors have successfully been used to treat 
patients with X-linked severe combined immunodeficiency (X-SCID), but some patients 
developed leukemia afterwards (Kohn, Sadelain & Glorioso 2003). Lentiviral vectors have 
naturally a better integration profile into less harmful areas, and a lot of research 
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concentrates on targeted integration of the transgenes to safer locations (Bushman 2007, 
Schenkwein et al. 2013).  
Non-viral vectors offer a safe means of gene transfer. DNA can be transferred as naked 
plasmid, complexed with lipids or polymers, or encapsulated inside nanoparticles. Physical 
methods, such as electroporation, gene gun, ultrasound, and hydrodynamic delivery, can 
be used to weaken the cell membrane in order to facilitate the gene delivery into the target 
cell nucleus (Li, Huang 2000). Non-viral vectors cause low immune responses, they can be 
produced quite easily in large quantities, and transgenes do not have size limits. However, 
transduction efficiency remains relatively low and the gene expression is transient 
(Ibraheem, Elaissari & Fessi 2014).  
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3 Aims of the Study
The overall aim of this thesis was to study the possibilities to promote the development of
VEGF-based pro-angiogenic therapies.
The specific aims of this thesis were as follows:
I) To study the structural and functional role of cysteines Cys-25, Cys-44, and
Cys-53 at the dimer interface of VEGF-D???C.
II) To  compare  different  VEGFR-2  ligands  for  their  ability  to  induce  VEGFR-2
activation, complex formation with neuropilins, downstream signaling, EC
proliferation, tube formation, and acute vascular permeability.
III) To investigate the angiogenic properties of Slit2 in vitro and in vivo as a single
factor as well as in combination with Vammin and VEGF-D???C.
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4 Materials and Methods
The materials and methods used in the articles I-III are summarized in the following tables
(Tables 2-8) and are described in more detail in the original publications.
4.1 MATERIALS
Table 2. Cell lines and animal models.
Description Source Used in
Cell line
HEK293T Human embryonic kidney cells, stably expressing
the large T-antigen
ATCC: CRL-11268 I, II
Sf9 Spodoptera frugiperda IPLB-Sf-21-AE cells Invitrogen I, II
High FiveTM Trichoplusia ni BtI-Tn-5B1-4 cells Invitrogen I, II
Ba/F3-VEGFR-2 Murine bone marrow-derived pro-B cells stably
expressing the VEGFR-2 ectodomain fused to the
intracellular domain of the erythropoietin
receptor
Achen et al. 1998 I
Ba/F3-VEGFR-3 Murine bone marrow-derived pro-B cells stably
expressing the VEGFR-3 ectodomain fused to the
intracellular domain of the erythropoietin
receptor
Achen et al. 2000 I
PAE-KDR Porcine aortic endothelial cells stably expressing
VEGFR-2
Waltenberger et al. 1994 I,II
PAE-Flt4 Porcine aortic endothelial cells stably expressing
VEGFR-3
Pajusola et al. 1994 I
HUVEC Primary human endothelial cells from umbilical
vein
Kuopio University Hospital
Maternity Ward
II, III
Animal Model
NZW rabbit Healthy New Zealand White rabbit I-III
Table 3. DNA constructs generated for BV production and/or protein expression.
Expression plasmid Source Protein purification Used in
pBVboostFGII-VEGF-D???C-His This work (I) Metal Affinity Resin I, II
pBVboostFGII-VEGF-D???C-His mutants This work (I) Metal Affinity Resin I
pBVboostFGII-VEGF-A121-His This work (I) Metal Affinity Resin I, II
pBVboostFGII-His-VEGF-A121 This work (II) Metal Affinity Resin II
pBVboostFGII-VEGF-A165-His This work (II) Metal Affinity Resin II
pBVboostFGII-His-VEGF-A165 This work (II) Metal Affinity Resin II
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pBVboostFGII-sVEGFR2-Fc This work (I) Protein A Sepharose I, II
pBVboostFGII-His-Vammin This work (II) Metal Affinity Resin II, III
pBVboostFGII-His-VEGF-ENZ7/PlGF
chimeras 9 and 33
This work (II) Metal Affinity Resin II
pAdCMV-sNrp1-Fc This work (II) Protein A Sepharose II
pAdCMV-sNrp2-Fc This work (II) Protein A Sepharose II
Table 4. Adenoviral vectors.
Vector Description Source Used in
AdSlit2 Adenovirus expressing human Slit2 under
the CMV promoter
A.I. Virtanen Institute III
AdVammin Adenovirus expressing snake venom
Vammin under the CMV promoter
A.I. Virtanen Institute III
AdVEGF-D???C Adenovirus expressing human VEGF-D???C
under the CMV promoter
A.I. Virtanen Institute III
AdCMV Empty adenovirus with the CMV promoter A.I. Virtanen Institute III
Table 5. Primary antibodies.
Antibody Description Source Application Used in
VEGF-D, MAB286 Mouse monoclonal anti-human Ab R&D Systems WB I
p-VEGFR2 Tyr-1175 Rabbit monoclonal anti-human Ab Cell Signaling WB I-III
VEGFR2 Rabbit monoclonal anti-human Ab Cell Signaling WB I-III
p-Akt Ser-473 Mouse monoclonal anti-human Ab Cell Signaling WB I
Akt Rabbit polyclonal anti-human Ab Cell Signaling WB I
VEGFR3 Rabbit polyclonal anti-human Ab Abcam IP, WB I
p-Tyr, clone 4G10 Mouse monoclonal Ab Upstate WB I
FLAG M2 Mouse monoclonal Ab Sigma EIA I
IgG (Fc) - AP Goat polyclonal anti-human Ab Sigma EIA I
p-VEGFR2 Tyr-951 Mouse monoclonal anti-human Ab Cell Signaling IP II
p-VEGFR2 Tyr-996 Rabbit polyclonal anti-human Ab Cell Signaling IP II
p-VEGFR2 Tyr-1212 Rabbit monoclonal anti-human Ab Cell Signaling IP II
p-VEGFR2 Tyr-
1054/Tyr-1059
Rabbit polyclonal anti-human Ab Abcam IP II
p-Erk1/2 Thr-
202/Tyr-204
Rabbit monoclonal anti-human Ab Cell Signaling WB II, III
Erk1/2 Rabbit monoclonal anti-human Ab Cell Signaling WB II, III
p-eNOS Ser-1177 Rabbit monoclonal anti-human Ab Cell Signaling WB II, III
eNOS Rabbit monoclonal anti-human Ab Cell Signaling WB II
p-Hsp27 Ser-82 Rabbit polyclonal anti-human Ab Cell Signaling WB II, III
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Hsp27 Mouse monoclonal anti-human Ab Cell Signaling WB II, III
Nrp1 (C-19) Goat polyclonal anti-human Ab Santa Cruz IP II
IgG (Fc) - HRP Goat polyclonal anti-human Ab Sigma EIA II
CD31 Mouse monoclonal anti-human Ab Dako IHC III
?-SMA Mouse monoclonal anti-human Ab Sigma IHC III
p-NOS3 Ser-1177 Goat polyclonal anti-human Ab Santa Cruz WB III
eNOS/NOS Type III Mouse monoclonal anti-human Ab BD Biosciences WB III
GAPDH Mouse monoclonal anti-rabbit Ab Santa Cruz WB III
Ab, antibody; AP, alkaline phosphatase; EIA, Enzyme immunoassay; Fc, Fragment crystallizable region;
HRP, horseradish peroxidase; Ig, immunoglobulin; IHC, immunohistochemistry; IP, immunoprecipitation;
WB, Western blot
Table 6. Reagents and kits.
Reagent name Description Source Used in
QuikChange Site-directed
mutagenesis kit
Generation of mutations into VEGF-D???C
plasmid
Stratagene I
Gateway Cloning reagents Cloning cDNAs into expression vectors Invitrogen I-III
FuGENE HD transfection
reagents Plasmid DNA transfection Roche I
BD TALON Metal affinity resin Recombinant protein purification Clontech I, II
Protein A-Sepharose Recombinant protein purification and
pulldown
GE Healthcare I, II
HiTrap desalting column Buffer change after protein purification GE Healthcare II
DC Protein assay kit Measuring total protein concentration BioRad I
BCA Protein assay kit Measuring total protein concentration Thermo
Scientific
I-III
PAGE Blue Protein Stain Staining in-gel proteins Fermentas I
G418 Eukaryotic cell selection InVivogen I, II
Zeosin Eukaryotic cell selection Invitrogen I
Puromycin Eukaryotic cell selection InVivogen I
Cell Titer Blue reagent Measuring metabolic capacity of cells Promega I
p-nitrophenyl phosphate Substrate for alkaline phosphatase Sigma I
TMB reagent Substrate for horseradish peroxidase Sigma II
Protease inhibitor Inhibition of protease activity in extracts Roche I-III
Phosphatase inhibitor Inhibition of phosphatase activity in
extracts
Roche I-III
SuperSignal West Dura
Extended Duration Substrate
Chemiluminescence-based detection of
proteins
Pierce I-III
Restore Western blot Stripping
Buffer
Removal of antibodies from nitrocellulose
and PVDF membranes
Pierce I-III
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rhVEGF-C Recombinant human VEGF-C Kari Alitalo II
rh-sVEGFR3-Fc Recombinant human soluble VEGFR-3
IgG Fc fragment fusion
Kari Alitalo II
EG00229 Nrp antagonist Ark
Therapeutics
II
Protein G Agarose Immunoprecipitating proteins out of cell
lysates
GE Healthcare II
MTS-reagent Determining relative amount of living
cells
Promega II
V2a kit Evaluation of in vitro tube formation TCS Cellworks II
Domitor Anaesthetizing rabbits Orion I-III
Ketalar Anaesthetizing rabbits Phizer I-III
Evans blue dye Binds serum albumin, for analyzing
vascular leakage
I-III
Sonovue Ultrasound contrast agent Bracco III
Table 7. TaqMan gene expression assays and DNA oligonucleotide primers for SYBR Green
based quantitative PCR.
Gene
TaqMan® Gene Expression
Assay/Primer sequence Used in
18S Eukaryotic 18S rRNA Hs99999901_s1 III
B2M Beta-2 microglobulin hForw: tagaggtggggagcagagaa
hRev: tcccccaaattctaagcaga
III
Robo1 Roundabout, axon guidance receptor,
homolog 1
hForw: cagactggcgacctcacaat
hRev: ccatccacggctacagtctg
rForw: aaggcacaactggaggtacg
rRev: tgctcccttgtttcctcgtc
III
Robo4 Roundabout, axon guidance receptor,
homolog 4
hForw: cttctccccgcttgtctctg
hRev: gccaggcaaccagagctt
rForw: tatggctacatcggcgttcc
rRev: gagctgaccaaactggctct
III
STC1 Stanniocalcin-1 Hs00174970_m1
rForw: gaagtcatccagcaccccaa
rRev: gcctcctgttgaagtcagct
III
NR4A1 Nuclear receptor subfamily 4, group A,
member 1
hForw: tgactactatggcagcccct
hRev: aggaaaagaaggctggaggc
III
ADAMTS1 A disintegrin and metalloproteinase with
thrombospondin motif type I
hForw: agctggttgtgatcgcatca
hRev: tgccattgttcctggatccc
III
IGFBP5 Insulin-like growth factor binding protein 5 hForw: tgctgtgtacctgcccaatt
hRev: cactcaacgttgctgctgtc
III
AQP3 Aquaporin 3 hForw: gctacctacccctctggaca
hRev: agttgaagcccatggaggtg
III
PLVAP Plasmalemma vesicle-associated protein hForw: agaaggtggagaaggaggct
hRev: ggtcttgatgcaggtgtcca
III
VEGF-A Vascular endothelial growth factor A hForw: agggaaaggggcaaaaacga
hRev: cgcgagtctgtgtttttgca
III
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TGF-? Transforming growth factor-? hForw: agaagaagcaggccatcacc
hRev: gtttctgagtggcagcaagc
III
Hs, human; s1, mRNA or genomic; m1, mRNA; h, human; r, rabbit, Forw, forward primer; Rev, reverse
primer
4.2 METHODS
Table 8. Summary of the methods.
Method Description Used in
Homology modeling Constructing a model of protein structure I
Gateway cloning Construction of vectors for protein and viral vector
production
I-III
Stepwise elongation of sequence-PCR Serial PCR method with multiple mutagenic primers I
Gateway chimeragenesis Combining two independent fragments with PCR I
Site-directed mutagenesis Generation of mutations into VEGF-D???C plasmid I
Cell culture Cell culture for various assays I-III
Plasmid DNA transfection Introduction of plasmid DNA into cells I, II
Production of baculoviral vectors Transfection, concentration, titering I, II
Production of adenoviral vectors Transfection, concentration, titering III
Recombinant protein production Production of proteins in High Five insect cells
following baculovirus infection or in 293T cells
following plasmid transfection
I, II
Recombinant protein purification Purification of His-tagged or Fc-conjugated proteins
from insect or mammalian cells
I-II
Measurement of total protein
concentration
Measuring total protein concentration after protein
purification and from cell and tissue lysates
I-III
Western (immuno-)blotting Detection of proteins I-III
Pulldown assay Precipitation of protein complexes I
Cell viability assay Measurement of the number of living cells I, II
Binding affinity measurement Measurement of the receptor binding affinities of
VEGF proteins
I, II
Phosphorylation assay Analyzing the activation of cellular receptors and
downstream signaling cascades from cells after
recombinant protein or viral vector treatment
I-III
Viral vector transduction Introduction of viral vector into cells III
Immunoprecipitation Precipitation of proteins out of cell lysates with
antibodies
I, II
Stability assay Measurement of the stability of different proteins I
Tube formation assay Evaluation of VEGF-induced in vitro tube formation II
Immunofluorescence staining Preparation of cell and tissue samples for analysis
with confocal and multiphoton microscopy
II, III
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In vivo experiments Anesthesia, sacrifice I-III
Miles assay with recombinant proteins I, II
Intramuscular injections with adenoviral vectors III
CPS ultrasound imaging for analyzing blood
perfusion III
Modified Miles assay for vascular permeability III
Immunohistology Fixation, embedding, sectioning, antibody staining III
Imaging Light microscopy II, III
Confocal and multiphoton microscopy II, III
RNA isolation and qRT-PCR Analyzing gene expression from cells and tissues III
RNA-Seq Creation of sequence library from the genome III
Statistical analysis Student’s t-test III
One-way ANOVA and Bonferroni’s corrected t-test II, III
ANOVA, analysis of variance; CPS, contrast pulse sequence
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5 Results and Discussion
The following chapter presents the main results of studies I-III.
5.1 IMPROVING VEGF-D???C ACTIVITY (I)
VEGF family members are potential therapeutic candidates in conditions like CAD and
PAD.  Structurally,  VEGFs  belong  to  the  cysteine  knot  growth  factor  family,  and  they  are
characterized by eight conserved cysteine residues (Grunewald et al. 2010). VEGFs form
dimers,  which  are  covalently  linked  by  intersubunit  disulfide  bonds.  Unlike  other  VEGF
family members, VEGF-D???C and VEGF-C???C exist  as  a  mixture  of  covalently  and  non-
covalently bound dimers although they have the conserved cysteine residues (Cys-44 and
Cys-53),  which form the  intersubunit  disulfide  bonds in  other  VEGFs (Joukov et  al.  1997,
Stacker et al. 1999a). In addition, they have an unpaired cysteine (Cys-25) at the dimer
interface. In this study, we investigated the importance of these cysteines for the function of
VEGF-D???C via site-directed mutagenesis and testing the biological activity of the several
engineered VEGF-D???C forms. At the time the original article was in preparation, there
were no published structures of VEGF-C or VEGF-D (Leppanen et al. 2010, Leppanen et al.
2011). Thus, we used homology modeling for construction of a model for VEGF-D???C.
5.1.1 Conserved cysteines 44 and 53 are essential for VEGF-D???C function
First, the roles of the conserved cysteines Cys-44 and Cys-53 were analyzed for the function
of VEGF-D???C. When these cysteines were mutated to alanines (C44A and C53A), mutated
proteins lost their capability to bind to VEGFR-2, which was analyzed by precipitating the
mutant proteins from transiently transfected 293T cell media with sVEGFR-2-Fc (Figure
10A, I). The native VEGF-D???C and the mutant proteins were also produced in a larger
scale in insect cells and purified from the culture medium. However, we were unable to
purify the C44A mutant protein, despite it was successfully expressed, suggesting for
possible protein aggregation or instability. In non-reducing conditions, the native VEGF-
D???C migrated mainly as a monomer in SDS-PAGE, but a small dimer fraction was
detected due to existence of a covalent disulfide bond (Figure 10B, I). The C53A mutant
protein migrated entirely as a monomer (Figure 10B, I). Thus, the intersubunit disulfide
bonds are not able to form in the C53A mutant due to the lack of the other participating
cysteine. Taken together, these results reveal that Cys-44 and Cys-53 are essential for VEGF-
D???C structure and activity. An intrasubunit disulfide bond between Cys-44 and Cys-25
could have been formed in the C53A mutant, since these cysteines are in close proximity
according to our homology model (Figure 10C, I). The proximity of the cysteines to each
other was verified from the VEGF-C and VEGF-D crystal structures, and Cys-25 side chain
was shown to point toward the dimer interface, as our model predicted (Leppanen et al.
2010, Leppanen et al. 2011). This indicates that this intrasubunit disulfide bond formation is
possible in the native VEGF-D???C.
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Figure 10.  C25A mutant,  but not C44A or C53A, retains its  VEGFR-2 binding capability.  C53A
mutant is a monomeric protein, but C25A mutant has a better dimer to monomer ratio than the
native VEGF-D???C.  SDS-PAGE  was  performed  to  analyze  (A)  different  VEGFR-2  bound  VEGF-
D???C forms  precipitated  from  transiently  transfected  293T  cell  media  and  (B)  purified
recombinant  proteins  with  (A)  or  without  (A  and  B)  ?-mercaptoethanol  (?ME).  Proteins  were
either  detected  by  immunoblotting  with  an  antibody  against  VEGF-D  (A)  or  stained  using
Coomassie staining (B). Homology model of the VEGF-D???C dimer (C) shows the location of the
cysteines 25, 44, and 53 at the dimer interface.
5.1.2 Cys-25 mutation increases covalently bound dimeric VEGF-D???C fraction
Unlike cysteines 44 and 53, the unpaired Cys-25 could be mutated to alanine (C25A)
without losing the VEGFR-2 binding capability of the VEGF-D???C (Figure  10A,  I).  In
addition, the purified C25A mutant protein showed an improved dimer to monomer ratio
in SDS-PAGE in non-reducing conditions compared to the native protein (Figure 10B, I).
This implies that the C25A mutant is mainly a covalently bound dimer. Thus, it seems that
the unpaired Cys-25 in the native VEGF-D???C might  interfere  with  the  formation  of  a
disulfide bridge between Cys-44 and Cys-53 of the opposite monomers. Biological activity
of the C25A mutant was analyzed in Ba/F3-VEGFR-2 and Ba/F3-VEGFR-3 cell survival and
growth assays where it showed improved activity compared to the native VEGF-D???C
(Figure 11A, I). We also substituted several other amino acids at the VEGF-D???C dimer
interface to mimic the dimer interface seen in other VEGFs, in particular VEGF-A. VEGF-A
exists as a covalently bound dimer and shows high biological activity. We found that
substituting  Cys-25  of  VEGF-D???C with  the  hydrophobic  amino  acids  Isoleucine  (I),
Leucine (L), and Valine (V) resulted in the highest activity in cell survival and growth
assays, and these mutant proteins migrated almost entirely as covalently bound dimeric
forms in SDS-PAGE (Figure 11A and B, I). These results correlate well with the fact that
other mammalian VEGFs, besides VEGF-C, have either Leucine or Valine, and also VEGF-F
(VR-1) has Leucine, at the site corresponding to the Cys-25 of VEGF-D???C.
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Figure 11. Most of the C25 substitutions in VEGF-D???C result in improved activity and increased
dimer to monomer ratio. The ability of the modified VEGF-D???C forms in conditioned media of
transiently  transfected  293T  cells  to  induce  cell  growth  and  survival  in  Ba/F3-VEGFR-2  and
Ba/F3-VEGFR-3 cells was studied (A). SDS-PAGE was performed to analyze the migration of the
modified VEGF-D???C forms as monomeric or dimeric forms in non-reducing conditions (B).
Proteins were detected by immunoblotting with an antibody against VEGF-D.
5.1.3 Cys-25 mutation leads to improved protein stability
The receptor binding affinities as well as the VEGFR-2 and VEGFR-3 phosphorylation
capabilities of the most interesting Cys-25 mutant proteins were analyzed (Figure 12A-C, I).
The C25L mutant had higher affinity for VEGFR-2 and VEGFR-3 than the native VEGF-
D???C, but interestingly, the affinities of the C25A mutant for the receptors were weaker
compared to those of native VEGF-D???C (Figure 12A, I). The ability of the proteins to
induce  VEGFR-2  activation  was  analyzed  in  porchine  aortic  endothelial  cells  stably
expressing VEGFR-2 (PAE-KDR) by detecting the phosphorylation status of Tyr-1175, the
major phosphorylation site for VEGFR-2 signaling (Sakurai et al. 2005). In this assay, the
C25L mutant induced the most efficient phosphorylation, but again, the C25A mutant was
less effective than the native VEGF-D???C (Figure  12B,  I).  Furthermore,  the  C25L  mutant
induced phosphorylation of both VEGFR-2 and VEGFR-3 with lower concentrations and
increased kinetics when compared to the native VEGF-D???C (Figure 12C, I). The C25L
mutant was thus more potent than the native protein to activate VEGFR-2 and VEGFR-3 in
all experiments. However, in the case of C25A, the affinity measurements and VEGFR-2
phosphorylation data did not correlate with the increased protein activity seen in the cell
growth and survival assays (Figure 11A, I). The difference between these assays is that the
cell growth and survival assay is performed during 48 h but the affinity and
phosphorylation assays take place in minutes. This implies that the stabilities of the mutant
proteins might be increased, and this most clearly appears in the assays that last longer.
Indeed, the increased stability was verified in the assay where the C25L mutant protein
retained its binding capability to VEGFR-2 after incubation at 37°C but the native VEGF-
D???C did not (Figure 12D, I). This is in line with the nature of covalent bonds, which
require relatively high energies to be broken. Thus, it  is likely that by eliminating the free
Cys-25 from the VEGF-D???C, a disulfide bond is able to form between intermolecular Cys-
44 and Cys-53 leading to the increased stability of the engineered C25 mutant proteins. In
the literature, there are also examples that disulfide-links have led to the stabilization of
proteins (Bjork et al. 2003, Hagihara, Mine & Uegaki 2007), and elimination of the free
cysteine in VEGF-C has also been shown to improve VEGF-C half-life (Anisimov et al. 2009,
Leppanen et al. 2010). In addition, VEGF-C and VEGF-D crystal structures were achieved
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only after Cys-25 was mutated to alanine forcing the proteins as covalently bound dimers
and, thus, more stable and homogenous (Leppanen et al. 2010, Leppanen et al. 2011).
Although the stability of the C25A mutant is most likely also increased leading to more
sustained receptor activation, its affinity towards VEGFR-2 and VEGFR-3 was shown to be
diminished due to the potential conformational changes. Furthermore, it was also found
that the substitution of Cys-25 with glycine (G) led to the inactivation of the protein (Figure
11A, I). The results suggest that the size of the substituting amino acid is highly important,
since the smaller size of both alanine and glycine compared to cysteine led to a
conformational change in the protein, which either disturbed the receptor binding or totally
blocked it. Leucine and cysteine are of similar size, and this substitution probably did not
change the protein conformation.
Figure 12. C25L mutant shows improved receptor affinities and activation kinetics than the
native VEGF-D???C due to enhanced protein stability. The relative VEGFR-2 and VEGFR-3 binding
affinities of  the purified recombinant proteins were measured using a solid phase competition
assays  (A),  and  their  ability  to  induce  VEGFR-2  and  VEGFR-3  tyrosine  phosphorylations  was
analyzed in PAE-KDR and PAE-Flt4 cells (B and C). The amount of the active protein capable of
binding to VEGFR-2 was determined after incubation at 37°C (D). The  values  in  A  and  D  are
expressed as mean ± SEM. TBS; Tris-buffered saline.
5.1.4 Biological significance of Cys-25
Results from Leppanen et al. (2011) showed that the C25A mutant retained its biological
activity in vivo. However, the overproduction of VEGF-D???C and the C25A mutant resulted
in  similar  angiogenic  effects  in  mouse  skeletal  muscle.  This  may  be  due  to  the  constant
expression of VEGF-D???C forms  from  the  AAV  vector  transduced  cells  making  the
increased stability of the mutant protein unnecessary. Our preliminary in vivo results with
the C25L mutant showed similar outcome after adenoviral delivery into rabbit skeletal
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muscle. Nevertheless, a similar cysteine to alanine mutation in VEGF-C was shown to lead
to improved arteriogenic activity, and there was a trend towards increased angiogenic
activity in mouse muscle after gene delivery with AAV vector, implying that stabilization
of the protein could also be beneficial in vivo (Anisimov et al. 2009). This would be of course
highly useful in pro-angiogenic therapies. It is not clear why the extra cysteine exists in the
structures  of  VEGF-D  and  VEGF-C.  Since  a  disulfide  bond  is  formed  by  oxidation  of  the
sulfhydryl side chain of cysteine, the changes in extracellular redox environment might
modulate the formation of either inter- or intrasubunit disulfide bridges in VEGF-D???C and
VEGF-C???C.  Thereby,  Cys-25  might  be  involved  in  controlling  the  activity  of  these
angiogenic proteins during development and in adult tissues.
5.2 CHARACTERIZING DIFFERENT VEGFR-2 LIGANDS (I, II)
VEGFR-2 is considered to be the main receptor mediating VEGF-induced angiogenic
effects, including EC proliferation, migration, survival, and vascular permeability (Shibuya,
Claesson-Welsh 2006). VEGFR-2 ligands, VEGF-A121, VEGF-A165, Vammin, VEGF-ENZ7/PlGF
chimeras 9 and 33 (VEGF-E#9 and VEGF-E#33), and VEGF-D???C,  differ  in  their  primary
structures and have distinct receptor binding profiles (Grunewald et al. 2010). In this study,
we produced and purified these proteins and compared in parallel their ability to bind and
activate VEGFR-2 and coreceptors and to induce downstream signaling, cell proliferation,
tubulogenesis, and acute vascular permeability.
5.2.1 Receptor binding affinities and activation kinetics differ between VEGFs
Based on their VEGFR-2 binding affinities, VEGF-A121, VEGF-A165, Vammin, VEGF-E#9,
VEGF-E#33, and VEGF-D???C were  divided  into  high  and  low  VEGFR-2  affinity  groups.
VEGF-A121, VEGF-A165,  and  Vammin  bound  to  VEGFR-2  with  similar  affinities,  and  in
addition, they all bound to Nrp-1 and -2 but VEGF-A121 did so with lower affinity than
VEGF-A165 and Vammin (Figure 13, II). VEGF-E#9, VEGF-E#33, and VEGF-D???C bound to
VEGFR-2 with lower affinities than the high affinity ligands. VEGF-E#9 and VEGF-E#33
were also able to bind to Nrps to some extent, but VEGF-D???C did not show any binding.
VEGF-A165 and  Vammin  also  bound  to  heparin  (Figure  13,  II).  It  has  been  shown  that
VEGFR-2 D2 and D3 are responsible for ligand binding (Leppanen et al. 2010, Brozzo et al.
2012). Although the primary structures of different VEGFs vary, the three dimensional
structure of the receptor binding VHD region is highly similar in all family members. Thus,
it is likely that different VEGFs bind to VEGFR-2 with similar mechanisms. In the absence
of the ligand, the C-terminal domain of VEGFR-2 has been shown to block the catalytic
kinase domain activation, but after ligand binding and kinase activation, the closed
conformation of VEGFR-2 is relieved allowing downstream signaling molecules to be in
contact with VEGFR-2 (Manni et al. 2014). Interestingly, in contrast to VEGFR-2, the
VEGFR-1 ligands, PlGF and VEGF-B, have been shown to require distinct VEGFR-1 domain
binding for high affinity interactions (Anisimov et al. 2013a).
The Nrp binding region is not as conserved between different ligands, but most of the
Nrp binding VEGFs have a positively charged C-terminal tail ending with arginine. VEGF-
A165 also  has  a  minor  Nrp  binding  site  in  its  sequence  explaining  the  higher  affinity  of
VEGF-A165 for Nrps compared to VEGF-A121 (Parker et al. 2012). To test the importance of
the free C-terminal arginine tail, modified forms of VEGF-A isoforms were generated by
introducing  a  His-tag  to  the  C-terminus  of  the  proteins.  This  did  not  have  any  effect  on
VEGFR-2 binding affinity,  but  binding to  Nrps and heparin  was inhibited.  Unexpectedly,
Vammin  was  able  to  bind  to  Nrps  with  similar  affinity  as  VEGF-A165 (Figure  13B,  II),
although the C-terminus of Vammin is not as positively charged (Yamazaki et al. 2003).
However, without the presence of heparin, Nrp binding was clearly reduced indicating an
important role of heparin if a large Nrp binding domain is absent. VEGF-E#9 and VEGF-
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E#33 showed some binding to Nrps, since they have a C-terminal tail of PlGF-1 that
resembles the tail of VEGF-A121.
Figure 13.  Different  VEGF  family  members  have  distinct  VEGFR-2  binding  affinities  and
coreceptor binding profiles. The relative VEGFR-2 binding affinities of the purified recombinant
proteins were measured using a solid phase competition assay (A) and their capability to bind to
Nrp1, Nrp2, and heparin was also measured (B). The values are expressed as mean ± SD.
Although the binding mechanism of VEGFs to VEGFR-2 did not likely differ, the
activation and internalization kinetics of the receptor were different depending on the
ligand. VEGFR-2 Tyr-1175 is shown to be the major phosphorylation site for VEGFR-2
signaling (Sakurai et al. 2005). All of the VEGFR-2 ligands induced VEGFR-2 Tyr-1175
phosphorylation in human umbilical vein endothelial cells (HUVECs) over a broad range of
concentrations (Figure 14A, II). The high affinity ligands induced phosphorylation with
lower concentrations and at earlier time points, but the low affinity ligands needed a higher
protein concentrations and a longer stimulation time for VEGFR-2 Tyr-1175
phosphorylation (Figure 14A and B, II). These results reveal that the measured VEGFR-2
binding  affinity  of  the  ligand  correlates  well  with  its  ability  to  induce  VEGFR-2  Tyr-1175
phosphorylation. Receptor internalization occurred slower with the low affinity ligands,
thereby leaving the receptor at the cell membrane for a longer time following stimulation
(Figure  14C,  II).  Thus,  depending  on  the  ligand,  the  rate  and  efficacy  of  VEGFR-2
dimerization, activation, and subsequent internalization by endocytosis differ. VEGF-A
forms have been shown to be strong inducers of angiogenesis, and based on these results,
Vammin seems to act as efficiently. Lower affinity ligands, like VEGF-D???C, do not activate
VEGFR-2 as potently, but the signal may be more stable and long-lasting. VEGFR-2
continues to be phosphorylated in endosomes after internalization, and the signal may be
even stronger when coming from the intracellular compartments (Lampugnani et al. 2006).
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This is in line with our observations with the high affinity ligands that induced VEGFR-2
internalization more rapidly but also phosphorylated VEGFR-2 Tyr-1175 more effectively.
However, the strong activation and internalization of VEGFR-2 induced by the high affinity
ligands most probably leads to faster VEGFR-2 degradation (Ewan et al. 2006) than would
happen with the low affinity ligands.
Figure 14.  VEGFR-2  Tyr-1175  phosphorylation  and  receptor  internalization  are  induced  with
different efficacies. HUVECs were treated with indicated amounts of Vammin (V), VEGF-A165
(A165 or A), VEGF-A121 (A121), VEGF-E#9 (E#9), VEGF-E#33 (E#33), VEGF-D???C (D),  or  with
medium  control  for  15  min  (A)  or  for  variable  time  points  (B),  and  VEGFR-2  activation  was
detected after immunoblotting of the whole cell lysates with antibodies against VEGFR-2
phosphorylated  at  Tyr-1175  (pY1175)  or  total  VEGFR-2  (R2).  Alternatively,  HUVECs  were
treated with 50 ng/ml Vammin, VEGF-A165, and VEGF-A121,  with  500  ng/ml  VEGF-E#9  and
VEGF-D???C, or with medium control, stained for VEGFR-2, and the average intensity of VEGFR-
2 internalized inside vesicles was quantified (C). The data are presented as mean ± SEM.
5.2.2 VEGFs induce the same VEGFR-2 phosphorylation pattern and downstream
signaling
Since there are several other tyrosine phosphorylation sites besides Tyr-1175 in VEGFR-2,
their phosphorylation was also analyzed with the different VEGFR-2 ligands. It was shown
that all the tested VEGF ligands were able to induce phosphorylation of Tyr-951, Tyr-996,
Tyr-1054/Tyr-1059, and Tyr-1212, and the phosphorylation levels were found to be similar
when  VEGFs  were  used  at  concentrations  shown  to  induce  equal  VEGFR-2  Tyr-1175
phosphorylation (Figure 15A, II). This further verifies that the receptor activation
mechanism is similar between the ligands. Based on literature, the phosphorylation of Tyr-
1054/Tyr-1059 within the VEGFR-2 kinase domain is necessary for the kinase catalytic
activation, and recently, phosphorylation of Tyr-951 in the kinase insert domain was shown
to be required for downstream signaling also from Tyr-1175 (Kendall et al. 1999, Manni et
al. 2014). In contrast to VEGFR-2, VEGFR-1 tyrosine activation pattern may be different
depending on the ligand used for activation, since it has been shown that PlGF is the only
VEGFR-1 ligand capable of inducing Tyr-1309 phosphorylation (Autiero et al. 2003). All the
tested VEGFR-2 ligands were also able to similarly activate the main downstream signaling
molecules, namely Erk1/2, Hsp27, and eNOS (Figure 15B, II). The only differences were the
concentrations of the ligands needed for achieving similar VEGFR-2/downstream protein
phosphorylation levels. VEGF-A121 and VEGF-A165, which showed equal VEGFR-2 affinities
but differences in Nrp binding, induced equal downstream phosphorylation. This implies
that once VEGFR-2 gets activated, signals are relayed in highly similar ways inside the cell,
or at least the phosphorylation status of the molecules at the end of the main signaling
cascades leading to cell proliferation, migration, and permeability is similar regardless of
the ligand. Supporting this, it has previously been shown that Nrp binding does not have a
role in activation of Erk1/2 or Akt pathways (Zachary 2011). However, there have been
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reports about the enhanced phosphorylation of some specific signaling molecules due to
additional Nrp binding of the ligand, such as p38MAPK, p130Cas,  and  FAK,  leading  to
differences in cell migration and vessel branching (Kawamura et al. 2008, Evans et al. 2011,
Herzog et al. 2011). There are also some controversial results about Nrp binding in
increasing the affinity of VEGFs towards VEGFR-2 or Nrp having an additive effect on
VEGFR-2 kinase activation (Zachary 2011). Interestingly, PlGF and VEGF-B were recently
shown to induce distinct signal activation downstream of VEGFR-1 explaining the different
biological responses of these ligands (Anisimov et al. 2013a).
Figure 15.  Different VEGFR-2 ligands induce similar  VEGFR-2 tyrosine phosphorylation pattern
and the activation of Erk1/2, eNOS, and Hsp27. PAE-KDR cells (A) or HUVECs (B) were treated
with 50 ng/ml Vammin, VEGF-A165, and VEGF-A121, or with 500 ng/ml VEGF-E#9, VEGF-E#33,
and VEGF-D???C (A), or with indicated amounts of the recombinant proteins (B) for 15 min and
the  whole  cell  lysates  were  immunoprecipitated  (IP)  and  immunoblotted  (WB)  (A)  or
immunoblotted (B) with the indicated antibodies.
5.2.3 Nrp binding is required for full angiogenic potency
The exact mechanism how Nrps act in ECs has remained somewhat unclear (Zachary et al.
2009). Nrps have been shown to form complexes with VEGFR-2, and we also verified this
with confocal microscopy and co-precipitation (Figure 16A and B, II). VEGF-A165 and
Vammin, which have high affinity towards Nrp-1, induced clear internalization of Nrp-1
from the plasma membrane, and following stimulation with these ligands, Nrp-1 and
VEGFR-2 were shown to co-localize inside the cell (Figure 16A, II). Nrp-1/VEGFR-2
complexes have also been shown to locate in different vesicles than uncomplexed VEGFR-2,
and this may lead to the enhanced activation of downstream signaling molecules (Ballmer-
Hofer et al. 2011). Nrp-1 and VEGFR-2 were also co-precipitated from the cell lysates after
treatment with VEGF-A165 or Vammin (Figure 16B, II). However, the effects were stronger
with VEGF-A165, indicating again the importance of the two separate Nrp binding sites
found in VEGF-A165 (Parker et al. 2012). Previously, it has been shown that although VEGF-
A121 is  able  to  bind  to  Nrp-1  through  its  E8-encoded  domain,  it  is  unable  to  induce  Nrp-
1/VEGFR-2 complex formation (Pan et al. 2007b). In line with these results, we did not
detect either VEGF-A121-induced co-localization of Nrp-1 and VEGFR-2 or signal from the
co-precipitation assay (Figure 16A and B, II). The Nrp binding ligands also induced
increased cell proliferation and tube formation (in vitro angiogenesis assay), when
compared  to  ligands  that  did  not  bind  Nrp-1  (Figure  16C,  II).  VEGF-A121 showed
intermediate effects, since it is missing the second, E7-encoded, Nrp binding region found
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in VEGF-A165.  The ligands naturally  incapable  of  binding to  Nrps or  the  various  VEGF-A
forms modified from their C-termini were less effective in the cellular assays, even when
used at high concentrations (Figure 16C and D, II). These results again demonstrate that the
E8-encoded C-terminal arginine is essential for the high affinity binding between VEGF-A
and Nrp-1 (Parker et al. 2012). However, VEGF-A165 with  a  His-tag  at  the  C-terminus
efficiently induced tube formation at the highest concentration (Figure 16D, II). This is
likely  due to  the  existence  of  the  minor  Nrp binding site  at  E7.  Nrp ligands also  induced
enhanced  sprouting  and  branching  in  the  tube  forming  assay,  as  previously  observed
(Kawamura et al. 2008).
Although we did not find any molecular explanation for the role of Nrp in our signaling
data, Nrp binding was required for the maximal angiogenic potency of the ligands. There
are also differences in the ECM binding properties of the ligands (Grunewald et al. 2010),
and therefore, binding to HSPGs may contribute to the high angiogenic activity of VEGF-
A165 and Vammin. In addition, since Nrp and HSPG binding sites overlap, the modification
of VEGF-A165 from its  C-terminus also  disturbs  the  interaction with HSPGs,  and this  may
partly influence the reduced effects of the VEGF-A165-His. Nevertheless, the reduced effect
of VEGF-A121-His compared to VEGF-A121 in  the  tube  forming  assay  seems  to  be  Nrp-
specific, since VEGF-A121 does not bind to HSPGs. Taken together, the functions of Nrp and
HSPGs could be partly similar, thus sequestering VEGFs in close proximity to the signaling
receptors and possibly regulating VEGFR-2 signaling spatially or temporally. Nrp could
also attract some specific signaling molecules close to Nrp-1/VEGFR-2 complexes.
Figure 16. Nrp binding ligands induce Nrp-1/VEGFR-2 complex formation and enhanced
angiogenic potency. HUVECs were treated with 50 ng/ml Vammin, VEGF-A165, and VEGF-A121,
with 500 ng/ml VEGF-E#9 and VEGF-D???C, or with medium control for 15 (A) or 30 (A and B)
min and either stained for Nrp-1 followed by quantification of the average signal intensity of
internalized  Nrp-1  inside  VEGFR-2  positive  vesicles  (A)  or  immunoprecipitated  (IP)  with  an
antibody against Nrp-1 and immunoblotted (WB) for VEGFR-2 (R2) (B). HUVEC proliferation (C)
and in vitro angiogenesis  (tube  forming)  assays  (C  and  D)  were  performed  with  indicated
recombinant protein concentrations. The values in panel A are expressed as mean ± SEM and in
panels C and D as mean ± SD.
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5.2.4 Nrp binding of VEGFs does not influence acute vascular permeability
Excess increase in vascular permeability and the subsequent tissue edema are deleterious
dose-dependent side-effects of VEGFs when they are used for therapeutic vascular
formation (Yla-Herttuala et al. 2007). Since VEGFR-2 has been shown to be the main
mediator of vascular permeability (Joukov et al. 1998, Gille et al. 2001), we wanted to
analyze the possible differences between the several VEGFR-2 ligands in the induction of
vascular permeability by injecting recombinant VEGF proteins under the rabbit skin
(Figure 17A and B, II, I). Acute vascular permeability was seen in minutes indicating a
rapid activation of a signaling pathway downstream of VEGFR-2. The high affinity ligands,
VEGF-A121, VEGF-A165, and Vammin, induced acute vascular permeability at 1-10 ng
amounts, whereas low affinity ligands, VEGF-E#9, VEGF-E#33, and VEGF-D???C, were
needed in amounts starting from 1000 ng to induce similar effects (Figure 17A, II). These
results reveal that the capability of the ligands to induce acute vascular permeability
correlates well with the VEGFR-2 binding affinities as well as with their VEGFR-2
activation potentials. However, the most potent VEGF-D???C mutant, C25L, was not able to
induce acute vascular permeability below 1000 ng amounts (Figure 17B, I), although its
affinity towards VEGFR-2 was somewhat higher compared to the native VEGF-D???C
(Figure 12A, I). Because the higher activity of the mutant protein is mainly due to the
increased protein stability, it is likely that there are no major changes in the ability of the
C25L mutant to induce VEGFR-2 activation. Most probably, the C25L mutant would have
shown some effect at higher protein doses, since also amounts above 1000 ng of the native
VEGF-D???C induced a clear increase in acute vascular permeability.
Nrp/HSPG binding was not detected to have a role in acute vascular permeability
response, since VEGF-A165 and VEGF-A121 behaved similarly in this assay. However,
according to previous findings, VEGF binding to Nrp-1 may have an additive effect on the
increase in vascular permeability (Becker et al. 2005). Our results and also data published
by others (Pan et al. 2007a) suggest otherwise, which would further underline the value of
Nrp-1 binding in the angiogenic process, since the side-effects would not be increased
because of the high Nrp-1 binding affinity of the ligand. Also, in contrast to some previous
reports (Stacker et al. 1999b), we did not detect VEGFR-1 having a major role in acute
vascular permeability response, since the ligands incapable of binding to VEGFR-1 were
nevertheless able to induce acute vascular permeability dose-dependently.
Figure 17. All VEGFR-2 ligands induce acute vascular permeability but with different potency.
Acute vascular permeability effects in the rabbit skin induced by the indicated amounts of the
recombinant proteins (A and B).
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5.3 COMBINATION THERAPY (III)
VEGFs have a great potential as future gene medicines in the field of therapeutic
angiogenesis. In several studies, VEGFs have been shown to enhance blood flow in skeletal
muscles and in myocardium (Yla-Herttuala 2013). However, to increase the efficacy of pro-
angiogenic therapies, new blood vessels should be stabilized and the amount of tissue
edema minimized. In this study, we used two different VEGFR-2 ligands, Vammin and
VEGF-D???C, to induce angiogenesis in rabbit skeletal muscles after adenoviral gene
delivery, and combined the gene transfers with Slit2, a possible modulator of angiogenesis.
Due to the controversial reports about Slit2 function in the vasculature, we also wanted to
test its angiogenic properties as a single factor in a large animal model where the effects of
Slit2 have not been studied before.
5.3.1 Slit2 reduces VEGF-induced blood perfusion and vascular permeability
Previously, VEGF-D???C has been shown to induce an increase in blood perfusion in rabbit
semimembranosus muscles after adenoviral gene delivery (Rissanen et al. 2003). In this
study, the angiogenic potency of Vammin is also shown, and its effects were discovered to
be  stronger  than  those  induced  by  VEGF-D???C (Figure  18A,  III).  This  implies  that  the
VEGFR-2  binding  affinity  of  the  ligand  correlates  well  with  its  ability  to  induce
angiogenesis also in the rabbit semimembranosus muscles. Thus, the low VEGFR-2 affinity
ligand VEGF-D???C requires a higher adenoviral vector dose than the high affinity ligand
Vammin to be able to induce angiogenic effects in vivo. In this study, Vammin was used in
10-times lower amounts than VEGF-D???C, but VEGF-D???C still did not have as strong an
effect as Vammin. This may be due to differences in VEGF receptor and coreceptor binding.
Thus, in addition to VEGFR-2, VEGF-D???C also binds to VEGFR-3, and it might therefore
compete for binding between these two receptors in the rabbit semimembranosus muscles.
Vammin  is  a  ligand  for  VEGFR-2,  and  binding  to  Nrp  coreceptors  was  shown  to  further
enhance  the  angiogenic  potency  of  the  ligand  (Figure  16C,  II).  The  level  of  edema
formation, due to increased vascular permeability, depends on the VEGF dose and the
VEGFR-2 affinity of the ligand. In this study, the high VEGFR-2 affinity ligand Vammin
induced more edema than VEGF-D???C in the semimembranosus muscles (Figure 18B, III).
Lowering the VEGF dose would result in reduced vascular permeability, but the
widespread angiogenic effects would then also be lost (Rissanen et al. 2003, Korpisalo et al.
2011).
Slit2 has been shown to restrain VEGF-A-induced angiogenic responses (Jones et al.
2008, Marlow et al. 2010), and supporting this, perfusion and vascular permeability effects
were  decreased  when  Slit2  gene  transfer  was  combined  with  Vammin  or  VEGF-D???C
(Figure 18A and B, III). However, the blood flow was still increased when compared to the
control gene transfer. In the Vammin+Slit2 group, the perfusion even remained at a slightly
higher level than in the VEGF-D???C group without Slit2. Slit2 decreased vascular
permeability induced by Vammin more than permeability induced by VEGF-D???C in  the
co-treated animals. Thus, Slit2 decreased Vammin-induced vascular permeability while
retaining Vammin-induced increase in perfusion. This suggests that when used in
combination with Slit2, the VEGF dose could be kept quite high to stimulate widespread
angiogenic response with minimal edema.
In  previous  studies,  the  anti-angiogenic  effects  of  Slit2  have  been  shown  to  be  mainly
mediated through Robo4 (Yuen, Robinson 2013). Therefore, we analyzed its expression
levels in semimembranosus muscles (Figure 18C, III). Robo4 mRNA was expressed in
muscles, and the expression levels exceeded the levels of Robo1, the receptor claimed to
mediate mainly the pro-angiogenic effects of Slit2 (Yuen, Robinson 2013). This could favour
the activation of the anti-angiogenic Robo4 pathway in the rabbit semimembranosus
muscles. As a single factor, Slit2 had no detectable effects. These results suggest that in the
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semimembranosus muscles, Slit2 is unable to initiate an angiogenic response, but it can
modulate VEGFR-2 mediated angiogenic effects, possibly by activating Robo4.
Figure 18. Slit2 reduces Vammin- and VEGF-D???C-induced perfusion and permeability. Rabbit
semimembranosus muscle perfusion (A) and permeability (B) measurements were performed
six  days  after  gene  transfers.  Fold  change  in  Robo1  and  Robo4  expression  levels  in  rabbit
semimembranosus muscles was analyzed with qRT-PCR (C).  18S was used as an endogenous
control. 1010 vp of AdVammin and 1011 vp of AdCMV, AdSlit2, or AdVEGF-D???C were used. The
data are presented as mean ± SEM. *P<0.05, ***P<0.001.
5.3.2 Capillary enlargement and sprouting are affected by Slit2
Next, capillary enlargement and sprouting were analyzed from CD31-stained
semimembranosus muscles (Figure 19, III). Both Vammin and VEGF-D???C were able to
induce capillary enlargement, but Vammin more potently (Figure 19A and B, III). The size
of the capillaries correlated well with the measured blood perfusion levels. Combining Slit2
with either of the growth factors reduced the capillary size, and the effect of Slit2 was more
pronounced on Vammin-induced capillary enlargement (Figure 19A and B, III). The
sprouting of the capillaries inversely correlated with the amount of the capillary
enlargement. Vammin-induced enlarged capillaries were straight-lined with only few
capillary  junctions,  but  when  Slit2  was  combined  with  Vammin,  the  sprouting  of  the
capillaries was increased (Figure 19C, III). This is in line with the previous findings, where
high adenoviral VEGF-A dose was shown to induce capillary enlargement, but more
sprouting angiogenesis was observed with lower doses (Korpisalo et al. 2011). Thus, with a
lower  Vammin  dose,  we  expect  to  see  the  same  kind  of  increase  in  sprouting  than  with
Vammin+Slit2, but the angiogenic effects might be more local. When lowering the dose
further, the sprouting would eventually start to diminish and finally resemble the basal
situation. Similar effect is seen with a weaker angiogenesis-inducing growth factor, such as
VEGF-D???C, which showed only minor sprouting. Slit2 did not seem to have any effect on
the VEGF-D???C-induced sprouting. Neither did Slit2 alone have any effects in these assays.
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Figure 19.  Capillary  enlargement  is  reduced  but  more  capillary  sprouting  is  detected  in
Vammin+Slit2 combination groups. CD31 staining was done on paraffin-embedded rabbit
semimembranosus muscle cross-sections six days after gene transfers (A), and the mean
capillary  area  was  quantified  (B).  Whole-mount  CD31  staining  was  done  on  rabbit
semimembranosus muscle pieces six days after  gene transfers (C).  1010 vp of  AdVammin and
1011 vp of AdCMV, AdSlit2, or AdVEGF-D???C were used. Scale bars 50 µm in panel A and 100
µm in panel C.
5.3.3 Slit2 reduces eNOS activation and downregulates angiogenesis-related genes
In previous studies, Slit2 has not been shown to influence directly VEGFR-2 activation
levels, but instead, Slit2-Robo4 signaling has been shown to reduce or block the activation
of certain signaling molecules downstream of VEGFR-2 (Jones et al. 2008). We analyzed
VEGFR-2 activation in HUVECs after adenoviral gene transfers and verified that Slit2 did
not affect Vammin-induced VEGFR-2 Tyr-1175 phosphorylation level nor the total VEGFR-
2 amount. In addition, we did not detect any differences in the activation of the main
signaling pathways Erk1/2 and Hsp27 as Vammin was compared to Vammin+Slit2.
However, Slit2 reduced Vammin-induced eNOS phosphorylation at Ser-1177, and this was
also detected in rabbit semimembranosus muscles (Figure 20A, III). In the context of
VEGFR-2 downstream signaling, eNOS activation and the subsequent NO production are
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mainly linked to the pathway leading to the increased vascular permeability (Koch,
Claesson-Welsh 2012). However, eNOS-derived NO has also an impact on EC proliferation
and migration, and eNOS antagonist has been shown to inhibit VEGF-induced
angiogenesis (Babaei, Stewart 2002, Rissanen et al. 2003). Thus, the reduced eNOS
phosphorylation levels are at least one reason for the decreased Vammin- and VEGF-D???C-
induced angiogenic effects in rabbit semimembranosus muscles.
To identify other Slit2 target genes, we performed RNA sequencing (RNA-Seq) after
adenoviral transductions in HUVECs and identified 77 and 28 RNA transcripts regulated
by more than two-fold (reads per kilobase per million reads, RPKM > 0.5, FDR < 0.05) when
AdSlit2 was compared to AdCMV and AdVammin+AdSlit2 to AdVammin, respectively.
The downregulation of selected angiogenesis-related genes (Figure 20B, III) was validated
by qRT-PCR from additional replicates (Figure 20C, III). A similar trend in gene regulation
was observed with Stanniocalcin-1 (STC-1), Nuclear receptor subfamily 4 group A member
1 (NR4A1), A disintegrin and metalloproteinase with thrombospondin motif type I
(ADAMTS1), Insulin-like growth factor binding protein 5 (IGFBP5), Aquaporin-3 (AQP3),
Plasmalemma vesicle-associated protein (PLVAP), and TGF-?. VEGF-A showed
contradictory results probably due to interindividual differences between different HUVEC
donors. In addition, we detected the upregulation of STC-1 and NR4A1 when Vammin was
compared to control (Figure 20D, III). Previously, a link has been shown to exist between
NR4A1 and eNOS. NR4A1 has been shown to be upregulated by VEGF-A thereby
mediating many of the angiogenic effects of VEGF-A, for example by leading to increased
eNOS activation (Zhao et al. 2011). The same effect was now shown with Vammin, and Slit2
treatment led to both downregulation of NR4A1 and reduced eNOS phosphorylation. The
other genes presented in the Figure 20B and C have previously been shown to be involved
in cell proliferation, migration, and vascular permeability (Strickland et al. 2005,
Papadopoulos, Saadoun & Verkman 2008, Hatipoglu et al. 2009, Yasuoka et al. 2009,
Appleton et al. 2010, Jauhiainen et al. 2011), and their downregulation by Slit2 further
demonstrates its anti-angiogenic potency. In addition, Robo4 was shown to be the
predominant Robo receptor also in HUVECs supporting the anti-angiogenic effects of Slit2
in these cells (Figure 20E, III).
49
Figure 20. Slit2 reduces eNOS phosphorylation and downregulates angiogenesis-related genes.
Semimembranosus muscle lysates were prepared and immunoblotted with antibody against
eNOS phosphorylated at Ser-1177 (A). GAPDH was used as an endogenous control. 1010 vp of
AdVammin  (V)  and  1011 vp of AdCMV (C), AdSlit2 (S), or AdVEGF-D???C (D)  were  used.  The
data  are  representative  of  three  independent  experiments.  Fold  change  in  STC-1,  NR4A1,
ADAMTS1, IGFBP5, AQP3, PLVAP, VEGF-A, and TGF-? mRNA expression levels was analyzed in
HUVECs  after  adenoviral  transductions  with  RNA-Seq  (B)  and  from  additional  replicates  with
qRT-PCR  (C  and  D).  Fold  change  in  Robo1  and  Robo4  expression  levels  in  HUVECs  was  also
analyzed with qRT-PCR (E).  B2M was used as an endogenous control.  For the RNA-Seq data,
thresholds  of  FDR <0.05,  RPKM >0.5,  and  fold  change  >2 were  used.  The  qRT-PCR data  are
presented as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001.
Taken together, the angiogenesis-restraining effects of Slit2 were obvious in rabbit
semimembranosus muscles and in HUVECs. Evidently, Slit2 was able to especially reduce
the effects of Vammin, which was shown to bind to VEGFR-2 with high affinity and induce
comparable angiogenic effects as VEGF-A165 (Figure  13A  and  16C,  II).  Since  VEGF-A
upregulation has been shown in many pathological conditions, like in cancer,
atherosclerosis, and intraocular neovascular syndromes, leading to disease progression
through neovascularization (Byrne, Bouchier-Hayes & Harmey 2005), Slit2 could possible
be used also as an anti-angiogenic factor in the therapies of these diseases. However, Slit2
overexpression has been found in several tumors and cancer cell lines and there have also
been reports about the potential pro-angiogenic role of Slit2 (Wang et al. 2003, Sheldon et al.
2009). Thus, the actions of Slit2 should be studied context-dependently, and for example,
the relative amounts of Robo1 and Robo4 in a certain tissue can influence the outcome.
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6 Summary and Conclusions
The main conclusions of this thesis are:
I The  structure  of  VEGF-D???C can be modified into a more stable, covalently
bound dimeric form by eliminating the extra cysteine from the dimer interface.
This  leads  to  the  increased activity  of  the  VEGF-D???C variants. However, the
conserved cysteines in all VEGF family members are essential for the function
of VEGF-D???C.
II Different VEGFR-2 ligands bind and activate VEGFR-2 as well as the major
downstream signaling pathways with a highly similar mechanism, but with
different  potency.  The binding of  VEGF-A165 and Vammin to Nrp-1 results in
complex formation between VEGFR-2 and Nrp-1, and is likely to potentiate
pro-angiogenic  effects  of  these  growth factors,  including EC proliferation and
tube forming. However, only the VEGFR-2 binding affinity of the ligand seems
to correlate with the increase in vascular permeability, and it is not influenced
by Nrp-1 binding.
III The differences in the receptor and coreceptor binding profiles and affinities of
Vammin and VEGF-D???C are translated into different pro-angiogenic efficacies
in vivo. More physiological angiogenic responses can be obtained in rabbit
skeletal muscle when Slit2 is used in combination especially with a high
VEGFR-2 affinity ligand, such as Vammin. Slit2 reduces eNOS activity, which
may contribute to the decreased vascular permeability effect and capillary
enlargement and increased sprouting observed in Vammin+Slit2 treated
animals compared to Vammin treatment.
The  results  from  this  thesis  bring  new  information  about  the  angiogenic  properties  of
different VEGFR-2 ligands, and how the ligands could be modified for improving the pro-
angiogenic treatments for ischemic diseases. This could be achieved by generating novel
VEGF variants with altered receptor activating properties underlining the importance of
high affinity for Nrps. Also, this thesis introduces a new treatment strategy to optimize
angiogenic responses and reduce the side-effects induced by VEGFR-2 ligands.
The VEGF-D???C variants developed in the first study may be most beneficial in
applications where recombinant proteins are used to stimulate blood vessel growth. Short
half-life of the recombinant proteins is one of the hurdles when they are used for pro-
angiogenic therapies, where sustained protein concentrations are required. Thus, the
increased stability and activity of the VEGF-D???C variants make them interesting factors
for protein delivery. For gene delivery, however, this would not necessarily provide an
advance, since the constant protein expression may overcome the relevance of the increased
VEGF-D???C stability.  Based  on  the  results  from  the  second  study,  VEGF-D???C is also
potential choice for developing further its coreceptor binding properties. The angiogenic
potency of VEGF-D???C could  probably  be  improved  by  introducing  an  Nrp-binding
domain into its sequence, and the naturally moderate VEGFR-2 binding affinity of VEGF-
D???C would keep the side-effects at a relatively low level. The angiogenic responses
induced by VEGF-D???C can  also  be  modified  with  a  combination  therapy  with  Slit2,  as
seen in the third study. However, it seems to be more beneficial to modify the effects of the
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high VEGFR-2 affinity ligands rather than VEGF-D???C,  since  in  addition  to  lowering  the
side effects, Slit2 also affects angiogenic potency. The use of a high VEGFR-2 affinity ligand,
like Vammin, in combination with Slit2 ensures that the efficacy of the pro-angiogenic
therapy is retained while side-effects are minimized.
Taken together, this thesis describes ways to enhance the angiogenic potency of low
VEGFR-2 affinity ligands without increasing their side-effects and to control vascular
leakage induced by high VEGFR-2 affinity ligands without losing the widespread
angiogenic  response.  VEGFR-2 ligands can be  introduced to  tissues  either  as  recombinant
proteins or using gene therapy vectors, but for achieving the most efficient angiogenic
response, gene delivery seems to be the most promising choice. Optimization of the
properties of the pro-angiogenic factors is an important step towards improved therapeutic
effects.
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and Angiogenic responses
Vascular endothelial growth factors 
are potential therapeutic agents to 
induce blood vessel formation in 
ischemic tissues. When designing 
improved pro-angiogenic therapies, 
the knowledge of the biology of these 
growth factors is essential. In this 
thesis, the properties of different 
VEGFs were studied to identify key 
features affecting their angiogenic 
effects. Also, new treatment 
strategies in combination with Slit2 
are described to reduce vascular 
leakage in therapeutic angiogenesis.  
